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ABSTRACT 
COURTNEY JONES:  Segregation of Biological Functions of Heparan sulfate Structures 
(Under the direction of Jian Liu) 
 
 Heparan sulfate (HS) represents a major class of glycans that perform central 
physiological functions.  Heparin, a special class of HS polysaccharides, is an anticoagulant 
that inhibitss factors Xa and IIa via its ability to modulate the antithrombin (AT) mechanism.   
However, medicinal administration of exogenous heparin has been shown to elicit heparin-
induced thrombocytopenia (HIT) in 2-5% of patients.  This response results from a Type II 
hypersensitivity reaction to heparin-platelet factor 4 (PF4) complexes.  Studies have shown 
that the interaction of heparin and PF4 may, in part, be mediated by charge.  Emerging HS 
and glycosaminoglycan microarray techniques are used to interrogate HS‟s structure and 
function relationship to develop novel therapeutic agents.  However, availability of HS with 
specific sulfation patterns has been a limiting factor and impedes the accuracy of HS 
glycomics studies.  Although organic synthesis provides oligosaccharides, these may not 
fully represent the biological functions of polysaccharides.  Here, we present a study for 
developing an enzyme-based approach to synthesize a polysaccharide library with different 
sulfation patterns.  Using different combinations of biosynthetic enzymes, we synthesized 
eight unique polysaccharides. We discovered that polysaccharides without the iduronic acid 
residue displayed strong binding affinity to antithrombin and high anti-Xa and anti-IIa 
activities.  We also used this biosynthetic method to regulate the overall charge of 
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these glycans by enzymatically modulating the degree of sulfation in order to reduce the 
binding of these polysaccharides to PF4.  By employing a biosynthetic scheme, we generated 
different species of polysaccharides encompassing varying sulfation patterns.  We discovered 
that modulation of the amount of N-sulfation at the beginning of synthesis is the most 
important motif for decreasing the polysaccharide‟s propensity for PF4.  The anticoagulant 
activity of these polysaccharide species was maintained although their affinity for PF4 was 
decreased.  This enzyme-based synthetic approach could become a general method for 
discovering new HS structures with unique biological functions. 
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CHAPTER I: 
INTRODUCTION 
 Three major classes of biopolymers exist in nature: proteins, nucleic acids, and 
polysaccharides. Unlike proteins and nucleic acids, our understanding of polysaccharides is 
limited largely because of the structural complexity and the absence of methods for 
replicating polysaccharide molecules with high fidelity. The glycosaminoglycan (GAG) 
represents an important type of polysaccharide in mammals because of the wide range of 
biological functions encompassed by GAGs. The GAG family includes chondroitin sulfate 
(CS), keratan sulfate (KS), hyaluronic acid (or hyaluronan, HA), and heparan sulfate (HS). 
These GAGs differ in disaccharide structure, possible structural modifications, and biological 
function.   
 Heparin, a special form of HS, is a commonly used anticoagulant drug with a 
worldwide annual sale of more than $3 billion. In addition to anticoagulant activity, 
exploration of antiviral, anticancer, and anti-inflammatory activities for therapeutic purposes 
has been expanded in recent years. However, the structure activity relationship (SAR) of 
these polysaccharides has been difficult to study due to the difficulty to synthesize precise 
heparan sulfate structures.  Without SAR studies, it becomes impossible to systematically 
synthesize heparins with specific biological activities.  Within this chapter, the 
aforementioned biological activities of HS, the biosynthesis of HS, and the current strategies 
for studying heparan sulfate structures will be discussed. 
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Section 1:  Biological Functions of Heparan sulfate 
 Heparan sulfate (HS) is an ubiquitously expressed endogenous polysaccharide that 
intrinsically possesses various biologic functions ranging from viral infection to 
anticoagulation.  Its ability to affect these pathways is why heparin (an analog of HS) drug 
research remains popular.   
 HS is prevalent throughout the body and has been shown to be essential in many 
regulatory functions.  HS exists on cell surfaces in the form of heparan sulfate proteoglycans 
(HSPGs) and it is these HSPGs that have been proven to function as co-receptors for various 
signaling molecules.  HSPGs also play roles in cell to matrix adhesion, lipoprotein 
metabolism, both viral and parasitic infections, modulation of protease activity, and 
modulation in early embryonic development (1,2).  There is also suggestion that binding to 
the HSPG scaffold can protect proteins from proteolytic degradation (3).  There are a few 
main pathways where HS/heparin exhibits a key regulatory function, such as, viral entry, cell 
proliferation, the anticoagulation pathway, and inflammation.  HS‟s function is determined 
by its sulfation pattern and size.  
Antiviral Activity 
HSPGs can aid in herpes simplex viral entry (HSV-1) via the interaction with HS side 
chain.  Thus, using a soluble HS or heparin to compete with cell surface HSPG could block 
HSV-1 infection.  Although the exact mechanism of HSV-1 entry is not fully understood, it 
is known that entry via viral  glycoproteins B, C, and D (gB, gC and gD, respectively) is due 
to an interaction with cell surface HS.  Viral gB and gC‟s interaction with HS is important in 
cell-targeting (4-7).  Viral gD, in association with gB, gH, and gL, are involved in binding 
with the cell via cell surface receptors (8).   HS modified by 3OST-3 binds to gD and serves 
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as an entry receptor for HSV-1.   Given the fact that 3-O-sulfated glucosamine is rare in HS, 
this unique 3-O-sulfated HS could serve as a specific compound to inhibit HSV-1 infection.  
A glycoprotein D binding octasaccharide has been characterized as ΔUA-GlcNSIdoUA2S-
GlcNAc-UA2S-GlcNS-IdoUA2S-GlcNH23S6S and has a KD of 19 μM (9).  Further, 
Copeland and colleagues demonstrated that the inhibition of HSV-1 entry was achieved by 
using a 3-O-sulfated heparin octasaccharide that mimics the structure of the gD-binding 
octasaccharide.  This demonstrated for the first time that a specific HS oligosaccharide can 
be used to inhibit HSV-1 infection (9). 
Proliferative Activity 
 HSPGs have a role in regulating cell proliferation and growth.  These proteoglycans 
are able to interact with various growth factors such as vascular endothelial growth factor 
(VEGF) and fibroblast growth factor (FGF) and their corresponding receptors.  In the case of 
FGF and its receptor, FGFR, HS chains are the mediator of their interaction.  The mechanism 
of this interaction has not been fully elucidated, but there are two predictive models based on 
crystal structures, one bound with heparin and one without (Figure 1).   
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Figure 1:  FGF2:FGF1:heparin models.  (Adapted from Mohamadi, et. al (10))  (A) Panel 
A shows the 2:2:2 model.  (B) Panel B shows the 2:2:1 model.  FGFR is represented in 
green, FGF is represented in yellow, and heparin is represented in the red spherical model. 
 
In the first model, heparin was absent in the crystal; however, the crystal suggested a 2:2:1 
(FGF2:FGFR1:heparin) ratio due to a cleft between two FGF2/FGFR1 complexes.  In the 
second model where the crystal was soaked with heparin, the model suggests a 2:2:2 ratio, 
wherein two heparin molecules occupy the cleft (10,11).  In the study of these interactions, 
there is one common thread, the minimal structure of the HS polysaccharide needed for this 
interaction to occur.  Previous studies have shown that the HS polysaccharides that are able 
to give rise to proliferative activity need a minimal disaccharide structure of IdoA2S–GlcNS 
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for binding.  But, the incorporation of 6-O-sulfation within the polysaccharide is required for 
activity (11). 
 Inflammation 
 In response to tissue injury or pathogen infections, the multi-step process that is 
involved in recruiting chemokines is initiated.  Endothelial cell surface HSPG has been 
demonstrated to play an essential role in the inflammatory response (12).  It has been shown 
that chemokines bind to heparin because most chemokines are highly positively-charged 
polypeptides which contain patches of basic residues at heparin and HS binding sites (13).  
The chemokine and HS interaction are believed to be essential for the presence of 
chemokines on the luminal surface of endothelial cells.  Furthermore, HS binds to cell 
adhesion molecules (such as L- and P-selectins), growth factors and growth factor receptors 
to regulate nearly every stage of leukocyte migrations through the blood vessel wall.  The 
sulfation patterns of endothelial HS direct the movement of neutrophil via the interactions of 
L-selectin and chemokines (14).  The heparin carrying 6-O-sulfo groups exhibit anti-
inflammatory effects by blocking the binding of HS and L- and P-selectins (15).  It is 
conceivable to develop HS-based anti-inflammatory agents (12).  
Anticoagulant Activity 
Heparin has been used as an anticoagulant drug for decades.  Heparin is an exclusive 
product of mast cells, while HS is expressed ubiquitously.  The structures of heparin and HS 
are similar, however, heparin has higher contents of IdoUA and more sulfo groups per 
disaccharide unit.  Heparin achieves the anticoagulant activity by serving as a catalyst to 
accelerate the interaction of antithrombin (AT) and factor IIa or factor Xa to exert inhibitory 
activity.  Heparin and low molecular weight heparin (LMWH) remain the drugs of choice for 
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the treatment of arterial and venous thrombotic disorders (16).  The major side effect of 
heparin drug is heparin-induced thrombocytopenia (HIT) because the binding of heparin to 
platelet factor 4 (PF4) leads to the aggregation of platelets.   
 Clinical studies have clearly demonstrated the benefits of treating cancer patients 
using heparin, especially LMW heparin (17).  The association between thrombotic diseases 
and cancer has been known to oncologists for a long time.  Administration of LMW heparin 
has improved the survival of the patients with small cell lung cancer from 29.5% to 51.3%, 
while warfarin (another commonly used anticoagulant drug) did not exhibit the anticancer 
activity (18).  In addition, treatment of advanced breast cancer patients with a combined 
chemotherapy with LMW heparin has reversed or stabilized the progression of the tumors 
(19).  Although the molecular mechanism for the link of cancer and coagulation is not 
completely clear, it is believed that the saccharide structures exhibiting the anticancer activity 
are different from those carrying anticoagulant activity as determined in a mice model 
(20,21).  The activities of these saccharides are a key example for how specific structures can 
be used for specific functions. 
Section 2:  Side-effects of Medicinal Heparin Administration 
 Although heparin is the number one drug used for anticoagulation, there are some 
side-effects associated with its use.  These side-effects are due to the highly negatively 
charged heparin‟s ability to interact with various protein targets by charge-charge 
interactions. 
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Heparin Induced Thrombocytopenia (HIT)  
 Heparin induced thrombocytopenia occurs in two clinical forms, HIT type I and HIT 
type II.  HIT type I is reversible, while type II remains the most detrimental side-effect of 
heparin administration.  Although it only occurs in 0.2-5% of patients who receive heparin, 
this hypersensitivity reaction can lead to the potential loss of limbs or death (22,23).  The 
exact mechanism of how heparin mediates this response remains unclear, but there have been 
great strides made into this study. 
Pathology of HIT and Platelet Factor 4’s Role 
 When platelets become activated due to vascular injury, they release platelet factor 4.  
The type II form of HIT occurs when platelet factor 4 becomes bound to heparin.  This 
complex attracts immunoglobulins, such as IgG and initiates the immune response (Figure 2).   
Platelet factor 4 is a highly positively charged protein released by platelets during 
coagulation.  Under normal physiological conditions, PF4 is implicated in many biologically 
relevant pathways, such as accelerating thrombin/antithrombin complex formation as well as 
various immune mediated responses (24).  However, PF4, during coagulation, can displace 
antithrombin from HSPGs on the cell surface and create a highly coagulant or thrombotic 
surface.  PF4 in the blood stream can interact with exogenous (or medicinal) heparin and 
yield macromolecular complexes of heparin and PF4 (25).   
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Figure 2: A schematic of the consequences of unwanted interactions between platelet 
factor 4 and heparin. 
 
Studies of PF4 and heparin interaction 
 Protein-polysaccharide interactions have been studied in various ways, including 
mass spectrometry, nuclear magnetic resonance and other biophysical techniques.  In 
particular, the interaction between PF4 and heparin have been studied from two perspectives: 
1. The perturbation of PF4 structure due to heparin binding and 2. The formation of 
macroparticles formed by their interaction.  Using site-directed mutagenesis and NMR,  
Mayo et al determined the arginine residues are the most critical for binding to heparin, 
followed by lysine (Figure 3) (21,24). 
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Figure 3: Critical residues in PF4 for interaction with heparin.  This figure shows the 
arginines and lysines (in green) responsible for interaction with heparin.   
 
Also, continued studies by Arepally and collaborators suggest that the heparin:PF4 
cluster size can affect its interaction with antibodies, wherein the cluster size is determined 
by the ratio of heparin to PF4.  This ratio is important in order to neutralize the overall 
surface charge of the macromolecule (26). 
Section 3: Structural Diversity of Heparin and Heparan sulfate (HS) Structures 
Heparin versus Heparan sulfate 
 HS is considered the king of the GAG family because of its diversified biological 
functions and clinical applications.  HS is present in both invertebrates and vertebrates in 
large quantities (27,28).  The typical length of HS is about 5 to 70 kDa, or 10 to 200 
disaccharide repeating units (29,30).  HS chains can be anchored by a core protein on the 
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surface of cells, known as proteoglycans, or pericellularly linked to the basement membrane 
in the extracellular matrix (29).  The anticoagulant heparin is an exclusive product of mast 
cells and, as previously mentioned, contains higher levels of sulfo groups and more iduronic 
acid than HS(16).  Both heparin and HS consist of a repeating disaccharide unit of 
glucosamine and either glucuronic or iduronic acid with various sulfations as shown in 
Figure 4. 
 
Figure 4:  Disaccharide repeating units of HS.  Sulfation (R=-SO3) at Carbon 6 (known as 
6-O-sulfo glucosamine) of glucosamine is common.  Sulfation at Carbon 2 of iduronic acid 
(known as IdoUA2S) is common.  Sulfation at Carbon 3 of glucosamine (known as 3-O-sulfo 
glucosamine) is rare.  Both N-acetyl (R‟=acetyl, GlcNAc) and N-sulfo glucosamine (R‟=-
SO3, GlcNS) are common.  N-unsubstituted glucosamine (R‟=-H, GlcNH2) is a low 
abundance component.  IdoUA±2S is present in both 
4
C1 and 
2
S0 conformations.  Both 
conformations are presented. 
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 Various sulfation patterns confer the functional selectivities of HS and heparin.  
These sulfations occur at the NH2, 3-OH, and 6-OH positions of glucosamine residue.  The 
hexuronic acid residues, including both iduronic and glucuronic acid, can include sulfo 
groups at the 2-OH position.  To further complicate the structure, the N-position of the 
glucosamine residue can also exist in the acetylated or unsubstituted form.  Different 
substitutions at the saccharide unit result in up to 32 variable structures for the disaccharide 
unit, which serves as the building block for the polysaccharide (31).  For a polysaccharide 
with a size of 20 disaccharide units, the theoretical number of permutations within the chain 
is to 10
32
.  However, it is believed that the actual number of variable polysaccharides are less 
than this value because of the substrate specificity restrictions of HS biosynthetic enzymes.  
Nevertheless, the existing permutations lead to the structure of HS from natural sources 
which exhibit vast structural heterogeneity and diversity.  Dissecting the relationship of 
structures and functions of has a large impact on understanding the physiological functions of 
HS, as well as, the development of HS-based therapeutic reagents. 
Section 4: Biosynthesis of Heparan sulfate (HS) 
Heparan sulfate Proteoglycans 
 HS can be found in almost all animal cells (27,32).  The lowest organisms where HS 
has been found are the metazoans ctenophora and cnidaria or jellyfish (33-35).  HS chains are 
attached to HS proteoglycans (HSPGs) either on the cell surface or within the extracellular 
matrix.  The amount and presence of HSPGs varies from cell to cell (33-35).  A HSPG 
consists of a core protein to which the HS chains are attached.  The core proteins are 
anchored to the cell membrane via a glycophosphatidylinositol (GPI)-anchor or a membrane-
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spanning domain.  HSPGs found in the extracellular matrix come from the core proteins that 
are secreted during the biosynthesis (36). 
HSPGs can be classified in two ways: part-time HSPGs and full-time HSPGs.  Part-
time HSPGs are proteins that have the ability to carry HS side chains, but can exist without 
HS side chains, also known as the non-proteoglycan form.  CD44, betaglycan and testican 
are a few examples of these proteoglycans.  Full-time HSPGs are either directly membrane-
bound or are linked to components within the extracellular matrix.  Full-time HSPGs include 
syndecans, glypicans, perlecan, agrin and type XVIII collagen (12,29,37,38).  A total of 13 
genes encode the full-time HSPGs: four syndecans (syndecan-1 to -4), six glypicans 
(glypican-1 to -6), and one isoform of each perlecan, agrin and type XVIII collagen although 
perlecan, agrin and type XVIII also have splice variants.  The average size of these protein 
cores range from about 32 to almost 500 kDa (Table 1).   
Table 1:  Summary of cell surface and extracellular matrix HS proteoglycans. 
Proteoglycans Size (amino 
acids) 
# of chains attached Gene Bank Accession Numbers 
    
Syndecan 310  5 CAA42851 (Homo sapiens) 
Glypican 558  3 CAA38139 (Homo sapiens) 
Perlecan 4391 3 P98160 (Homo sapiens) 
Agrin 2045 3 NP_940978 XP_372195 (Homo 
sapiens) 
Type XVIII 
collagen 
1516  3 AAC39658 (Homo sapiens) 
 
Syndecan and glypican are both cell membrane associated proteoglycans, while 
perlecan, agrin and type XVIII collagen are extracellular components (Figure 5).  Syndecan 
contains an integral membrane protein and glypican is anchored by glycosyl-
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phosphatidylinositol (GPI).  Perlecan, agrin and type XVIII collagen, although not directly 
associated with the plasma membrane, can be associated via integrins or other cell surface 
receptors (29).   
 
Figure 5: Schematic view of the HSPG.  The core proteins are show in colored tubes, while 
the HS chains are shown in blue lines.  The core protein of syndecan is a transmembrane 
protein, with 3-5 attachment sites in the extracellular domain.  The core protein of glypican 
attaches to the membrane through a glycosyl-phosphatidylinositol (GPI) anchor, with 1-3 HS 
attachment sites.  The core protein of collagen is not directly attached to the cell membrane; 
it has three potential HS attachment sites.  
 
Building the backbone 
The biosynthesis of HS has been the fundamental subject of studying the function and 
activity relationship of HS.  A detailed view of HS biosynthesis would aid in elucidation of 
the structure-function relationship of HS in different biological contexts.  In addition, a 
complete grasp of the biosynthesis mechanism would promote the development of the in 
vitro biosynthesis of HS or HS-like macromolecules for therapeutic purposes.  In the past 
decade, as a result of the sustained effort to understand the biosynthetic pathway of HS, all 
enzymes involved in HS biosynthesis have been cloned or purified, which greatly advanced 
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our knowledge of this essential biological process.  It should be noted that the availability of 
HS biosynthetic enzymes also provided the opportunity for conducting enzyme-based 
synthesis of HS polysaccharides (39,40). 
Synthesis of the building block   
HS biosynthesis takes place in the lumen of Golgi apparatus, where the sugar residues 
are assembled and modified by the actions of multiple Golgi membrane bound enzymes.  
However, the initial synthesis of building blocks occurs in the cytoplasm, not in the Golgi.  
These blocks are then transported into the Golgi lumen via an unknown mechanism for the 
subsequent modifications described below.  The synthesis requires access to various 
activated sugar donors including UDP-xylose (UDP-Xyl), UDP-galactose (UDP-Gal), UDP-
N-acetyl glucosamine (UDP-GlcNAc) and UDP-glucuronic acid (UDP-GlcUA), as well as, 
the sulfo donor 3‟-phosphoadenosine 5‟-phosphosulfate (PAPS) for the sulfation reactions.   
The UDP-Xyl, UDP-Gal and UDP-GlcUA are all derived from the activated glucose, 
namely UDP-glucose (UDP-Glc).  UDP-Gal arises from epimerization at the C4 position of 
UDP-Glc; while UDP-GlcUA arises from UDP-Glc via UDP-Glc 6-dehydrogenase.  The 
UDP-Xyl is synthesized from UDP-GlcUA in the Golgi apparatus by UDP-GlcUA (Figure 
6).  The biosynthesis of UDP-GlcNAc is more complex.  It starts from fructose 6-phosphate, 
and requires three enzymes, a transaminase, an N-acetyltransferase and a mutase, to generate 
GlcNAc 1-phosphate, which is then converted to UDP-GlcNAc by UDP-GlcNAc 
diphosphorylase.  Once synthesized, these UDP-sugars are transported into the Golgi lumen 
though specific nucleotide sugar transporters (Figure 6) (41). 
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Figure 6:  Schematic view of HS backbone synthesis.  For simplicity, the synthesis of 
UDP-GlcNAc is not shown.  The EXT family member of EXTL1 is also absent in the figure, 
which was shown to possess GlcNAcTII activity. 
= Core protein 
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The general schematic of sulfation of the HS chain by PAPS is shown in Figure 7.  
The biosynthesis of PAPS occurs in both the nucleus and the cytoplasm. Then PAPS is 
transported to the Golgi by PAPS transporter for HS biosynthesis (42).  
 
Figure 7: Schematic for the use of PAPS in sulfation via the sulfotransferases. 
  
Chain initiation 
The biosynthesis of HS is initiated by formation of a tetrasaccharide linkage to the 
core proteins: GlcUA β1-3Gal β1-3Gal β1-4Xyl β1-O-Ser, which also serves as the linkage 
for the biosynthesis of CS.  The formation of the tetrasaccharide linkage is catalyzed by the 
sequential actions of four glycosyltransferases, namely xylotransferase (XT), 
galactosyltransferase I (GalTI), galactosyltransferase II (GalTII) and glucuronosyltransferase 
I (GlcUAT1) (Figure 6) (43). 
 XT is the first enzyme that triggers the synthesis of the tetrasaccharide linkage at 
specific serine residues of the core proteins.  Two highly homologous XTs (XTI and XTII) 
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have been identified in vertebrates; however, only XT1 has been determined unambiguously 
to have XT activity (44,45).  The full length human XT1 has recently been expressed in 
mammalian cells in the active form and was shown to localize in the early cis-Golgi (46).  
Mechanisms of core protein attachment sites recognition by XT have attracted considerable 
attention, given the pivotal role of this enzyme in initiating synthesis of HSPG.  A Ser-Gly 
repeating dipeptide seems to be the minimum structural requirement for the xylosylation to 
occur, and a Glu or Asp residue of the core protein is often present in the vicinity of the Ser-
Gly sequence (47).  Nevertheless, how XT recognizes the substrate core proteins and selects 
the Ser residue is still an open question. 
Once the xylose is transferred to the core protein, the glycan moiety is elongated by 
two galactosyltransferases, GalTI and GalTII.  GalTI, belonging to the β1,4 GalT 
superfamily, transfers a galactose onto xylose to form Galβ1-4Xylβ1-O-Ser; while GalTII 
belongs to the β1-3 GalT superfamily, and subsequently adds another galactose to form 
Galβ1-3Galβ1-4Xylβ1-O-Ser.  Both GalTs were cloned and expressed, and their substrate 
specificities have been described.  They have been shown to be located in the early-medial 
cis-Golgi (48-50).  
Synthesis of the tetrasaccharide linkage is finalized by GlcUAT1, which is localized 
in the medial cis-Golgi (50).   It transfers GlcUA from UDP-GlcUA to the existing glycan 
chain to form GlcUAβ1-3Galβ1-3Galβ1-4Xylβ1-O-Ser.  The crystal structure of GlcUAT1 
has been solved with the UDP, Mn
2+
 and a substrate analogue Galβ1-3Galβ1-4Xyl, revealing 
that GlcUAT1 mainly recognizes the Galβ1-3Gal moiety, rather than the trisaccharide as a 
whole (51).  More interestingly, a recent study demonstrated that sulfation at the Galβ1-
3Galβ1- moiety can greatly influence the enzymatic activity of GlcUATI, possibly providing 
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a regulatory mechanism for proteoglycan biosynthesis (52).  In addition, sulfation of the 
galactose in the linkage region has only been seen in CSPG but not in HSPG, suggesting it 
may serve as a signal to direct subsequent GAG synthesis (53).  Moreover, evidence suggests 
that the synthesis of the tetrasaccharide linkage can be carried out by GlcUAT-P, a 
promiscuous glucuronosyltransferase that normally works on glycoproteins, thus providing a 
potential redundant mechanism for the linkage region synthesis (54).   
Chain polymerization 
The tetrasaccharide linkage to the core protein provides a common precursor for the 
biosynthesis of both HS and CS polysaccharide chains.  The critical step that separates 
polymerization of HS from that of CS is the addition of a GlcNAcβ1- unit instead of the 
GalNAcβ1- unit to the nonreducing end of the tetrasaccharide.  This step should not be 
confused with the polymerization reaction, where the GlcNAc unit is also incorporated due to 
the action of a different enzyme (55).  For clarity, the enzyme that adds GlcNAc to the 
linkage region is HS GlcNAc transferase I (GlcNAcT1), while the enzyme that adds GlcNAc 
to the growing HS chain is HS GlcNAc transferase II (GlcNAcTII) (Figure 6).  Two 
mammalian proteins encoded by EXTL2 and EXTL3, belong to the EXT (exostosin) gene 
family, have been proved to carry the GlcNAcT-I activity (56,57).  Their activities have been 
demonstrated in vitro using a synthetic tetrasaccharide linkage analogue, GlcUAβ1-3Galβ1-
naphthalenemethanol, as the acceptor.  However, the GlcNAcT-1 activity could not be 
detected using the natural tetrasaccharide linkage GlcUAβ1-3Galβ1-3Galβ1-4Xylβ1-O-Ser 
as the acceptor.  It has been proposed that hydrophobic residues on the core protein close to 
the linkage site are essential for the GlcNAcTI activity, which may attribute to the above 
mentioned discrepancy, as the naphthalenemethanol group has strong hydrophobic nature 
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(56).  Nevertheless, biochemical studies directly using HSPG core proteins as the acceptors 
of EXTL2 and EXTL3 are necessary to test this hypothesis.  In addition, genetic studies 
targeting EXTL2 and EXTL3 are essential to establish the specific roles of these two isozymes 
in initiation of HS biosynthesis.  It is important to note that a recent study of the boxer 
(EXTL3) mutant in zebra fish suggested that abolishing EXTL3 function causes severe 
reduction of HS biosynthesis, supporting the role of EXTL3 in initiating the synthesis of HS 
(58). 
Once the GlcNAc unit is coupled to the linkage tetrasaccharide, the polymerization 
for the synthesis of HS is committed by adding GlcUA and GlcNAc alternatively (Figure 6).  
The enzymes encoded by the members of the EXT gene family, EXT1 and EXT2, carry out 
the polymerization of HS backbone (3,59).  EXT1 and EXT2 are both bifunctional enzymes, 
exhibiting GlcUATII (distinguishing from GlcUAT1 that synthesizes the linkage region) and 
GlcNAcTII activities (Figure 6).  EXT1 and EXT2 are not redundant enzymes, instead, they 
form a complex and both are indispensable for the biosynthesis of HS in vivo (60).  The 
significance of heterocomplex of EXT1 and EXT2 in vivo are two-fold.  First, the complex 
helps direct the EXTs to the Golgi apparatus rather than the ER(60,61).  Secondly, mutations 
of either EXT1 or EXT2 could cause hereditary multiple exotoses, an inherited disease 
manifesting short stature and inequalities in limb length.  Moreover, the individual EXT 
isoform has markedly lower HS polymerase activity compared to the EXT1/EXT2 complex 
as determined by in vitro studies (62), providing additional evidence for the importance of 
complex formation.  It is important to note that EXT1 and EXT2 are not the only enzymes 
that possess GlcNAcT-II activity; EXTL1 and EXTL3 have also been demonstrated to be 
capable of adding GlcNAc residues to the growing HS chain in vitro (56).  But how the 
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GlcNAcT-II activity of EXTL1 and EXTL3 correlates to that of EXT1 and EXT2 is an 
intriguing question, especially considering that they do not possess any GlcUAT-II activity.  
One hypothesis is that EXTL1 and EXTL3 may play regulatory roles in HS biosynthesis 
since they may compete with the EXT1/EXT2 complex (56).  However, direct evidence 
supporting this hypothesis has been lacking, and the true functions of EXTL1 and EXTL3 in 
HS polymerization must wait for future genetic studies targeting these two enzymes. 
The crystal structure of EXTL2 has been solved in complex with the sugar donor 
UDP-GlcNAc, and in complex with UDP and the acceptor analogue GlcUAβ1-3Galβ1-O-
naphthalenemethanol, providing an excellent model for understanding the mechanism of 
action of EXT family members (63).  However, since EXTL2 is the shortest isozyme of the 
family and it aligns to the C-terminal GlcNAcT domains of other EXT members, its structure 
only helps to understand the GlcNAcT activity of EXT(L)s.  Detailed biochemical studies are 
needed to elucidate the functions of the N-terminal domain of EXT(L)s.  For some enzymes, 
more specifically EXT1 and EXT2, the N-terminal domain harbors the GlcUAT activity (64), 
and for others, EXTL1 and EXTL3, its function is still unknown. 
Modifications of the Backbone 
Once polymerized, the HS backbone (or N-acetyl heparosan) is subjected to a series 
of modifications that exponentially diversify the structures of HS.  The GlcUA units can be 
modified at two positions.  The configuration at C5 position can be changed from S to R by 
glucuronyl C5-epimerase (C5-epi), giving rise to the IdoUA unit; and both GlcUA and 
IdoUA can be sulfated at the C2 position by HS 2-O-sulfotransferase (2OST).  The 
modifications of GlcNAc residues take place at three positions.  The N-acetyl group of 
GlcNAc can be modified by N-deacetylase/N-sulfotransferase (NDST), a bifunctional 
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enzyme that removes the N-acetyl group and installs a sulfo group; and the C3 and C6 
position of glucosamine can be sulfated by HS 3-O-sulfotransferase (3OST) and HS 6-O-
sulfotransferase (6-OST), respectively (Figure 8). 
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Figure 8: Schematic view of the HS modifications.  (a) The HS modifications enzymes and 
their respective modification sites are shown on the disaccharide unit.  (b) HS modification 
pathway.  The number of isoforms in humans of each enzymes is shown in the parentheses 
after the name of the enzyme.  The sequence of the modifications shown only represents a 
general guide, and it is important to note that the HS modification mode in vivo may display 
some variations from the main theme. (c) Representative disaccharide structures with specific 
biological functions. 
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N-Deacetylase/N-Sulfotransferase 
NDST is the enzyme that initiates modification of N-acetyl heparosan.  N-sulfation of 
the glucosamine unit has been demonstrated to be essential for most of the subsequent 
modifications on HS, thus representing a critical step in HS biosynthesis (Figure 9) (43).  
NDST does not modify HS uniformly: instead, the N-sulfated glucosamine units are 
clustered, giving rise to the NS domain of HS, whereas the NA domain contains mostly the 
unreacted N-acetylated glucosamine (Figure 8) (28). 
 
Figure 9: Schematic of enzymatic function of NDST. 
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 NDST can be divided into two domains: the N-terminal deacetylase domain (within 
~600 amino acid residues of the N-terminus) and the C-terminal sulfotransferase domain 
(including about 280 amino acid residues).  Both domains have been expressed and proved to 
contain the anticipated activities (65,66).  In addition, NDST is a typical type II membrane 
bound protein with the transmembrane domain at the N-terminus.  
 Four isoforms of NDST have been identified in human and mouse (67-70).  The 
isoforms can be divided into two subgroups: NDST-1 and NDST-2 with 70% identities in 
amino acid sequence, and NDST-3 and NDST-4 with 80.4% identity.  Those four NDST 
isoforms have distinct tissue expression patterns.  NDST-1 and NDST-2 are expressed quite 
uniformly in different tissues, while the expression of NDST-3 and NDST-4 occurs 
predominantly in the brain (71).  Each NDST isoforms appears to have distinct deacetylase 
and sulfotransferase activities.  For example, NDST-3 has good deacetylase activity but very 
poor sulfotransferase activity, and NDST-4 shows the opposite with poor deacetylase activity 
and excellent sulfotransferase activity.  The biological significance of the variations of the 
enzymatic activities of NDST isoforms is not fully understood, but it has been proposed that 
it may help generate unique sulfation patterns on HS (71). 
A series of genetic studies of NDST-1 and NDST-2 have provided great insights onto 
the physiological functions of N-sulfation in model animals.  The Ndst-1 null mice die 
shortly after birth due to severe lung failure (43,72).  In addition to prominent defects in lung 
development, detailed phenotypic study of Ndst-1 deficient mice embryos at various 
developmental stages revealed they display conspicuous developmental defects at the 
forebrain, face and eyes (73), reinforcing the pleiotropic effects of NDST-1 in mammalian 
development.  The Ndst-2 null mice have also been generated, but in contrast to the 
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widespread effects of the Ndst-1 mutant; the only obvious defect is in connective tissue-type 
mast cell (74,75).  These cells are generally active during inflammatory processes, and they 
release various inflammation mediators such as heparin, histamine and mast cell protease.  
However, in the mast cells of the NDST-2 deficient mice, production of heparin is aborted, 
the amount of histamine release is greatly reduced, and mast cell proteases are lacking.  
These data suggest that NDST-2 plays a predominant role in mast cells in terms of HS 
sulfation.  Conversely, since NDST-2 deficient mice develop normally; otherwise, it seems 
that NDST-2 is dispensable in other tissues, where NDST-1 may play more dominant roles.  
Recently, NDST-1 has been knocked out in mice in a tissue-specific manner in endothelial 
cells and leukocytes, which helped demonstrate the essential roles of HS in inflammatory 
responses (14). 
 In comparison to the largely elucidated structure and function of the N-
sulfotransferase domain, the function of the N-terminal region of NDSTs is apparently 
understudied.  The N-terminal region, about 600 amino acid residues in length, contains the 
N-deacetylase domain (65).  However, we have extremely limited knowledge of the 
deacetylase domain because it has no homology with the other carbohydrate deacetylases.  
Thus, the mechanism for deacetylation is still elusive.  Understanding the deacetylation 
mechanism of NDSTs would be very informative, considering that varying NDST isoforms 
have distinct N-deacetylase activities.  The action of different NDSTs could implant 
information for the subsequent enzymatic modifications, which ultimately decide the overall 
structure of HS. 
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Glucuronyl C5 Epimerase 
The first modification that happens on the GlcUA residue is catalyzed by HS C5-epi, 
which converts the configuration of proton of the C5 position, thus generating IdoUA unit 
(Figure 10).  An N-sulfated glucosamine (GlcNS) is required at the non-reducing end of the 
GlcUA for the action of C5-epi, suggesting the C5-epimerization rigorously follows N-
sulfation (Figure 8) (28).  Switching from GlcUA to IdoUA has been suggested to give HS a 
more flexible structure because it is known that IdoUA adopts several pyranose ring 
conformations, including 
1
C4, 
4
C1 and 
2
S0, while GlcUA usually exists in 
4
C1 conformation 
(76).  In addition, IdoUA is a much more favorable substrate for HS 2OST, and the resultant 
IdoUA2S is essential for many biological functions (77-80).   
 
Figure 10: Schematic of C5-epimerase activity. 
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 Different from most other HS modification enzymes, only a single isoform of C5-epi 
is present in almost all species examined (with the exception of fish).  C5-epi is a fairly large 
protein with over 600 amino acids.  The epimerase catalytic domain has been tentatively 
assigned to the 220-230 residues of the C-terminus based on alignment to homologous 
proteins and biochemical studies (81). 
 The C5-epi has been shown to form a complex with HS 2OST in vivo, which is 
indispensable for correct Golgi localization of C5-epi (50).  Formation of the complex may 
have a substantial effect on the enzymatic activity of C5-epi.  The common substrate for C5-
epi and HS 2OST, GlcUA, may be channeled through the enzyme complex to achieve a 
higher efficiency of modification, as it is known that IdoUA2S is no longer a substrate for 
C5-epi (50,82).  The final ratio of the GlcUA/IdoUA presented in the HS may be actively 
regulated by this reaction. 
 The knockout mouse model of C5-epi has provided significant information about the 
physiological functions of the enzyme (83). C5-epi deficient mice died immediately after 
birth due to respiratory failure, apparently as a result of poorly developed lungs.  Other 
evident phenotypes include undeveloped kidneys, eye defects, various skeletal abnormalities 
such as shorter body length and excessive mineralization.  Close examination of HS from 
C5-epi
-/-
 mice shows that production of IdoUA is totally abrogated, while the proportion of 
GlcUA2S increased 3-fold and the 6-O-sulfation increased 5-fold.  The phenotypic 
differences between the C5-epi
-/-
 and NDST-1
-/-
 mice suggest that C5-epimerization plays 
unique roles in animal development, and IdoUA or IdoUA2S are specifically needed for 
certain cellular signaling processes. 
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 A recent study pointed out that human C5-epi is transcriptionally regulated by the β-
catenin-TCF4 transactivation complex, the terminal effector of the Wnt/β-catenin signaling 
pathway (84).  This study showed that there are two β-catenin-TCF4 cis-acting elements 
located in the enhancer region of the promoter; it also showed that ectopic expression of β-
catenin and TCF4 together significantly enhances the cellular level of C5-epi transcript along 
with its enzymatic activity.  Based on the evidence that HS is an important regulator of the 
interaction between Wnt and its cell surface receptor Fz (Frizzled), HS biosynthesis and Wnt 
signaling may be independent.  It raised the possibility that a feedback loop is present 
between an essential signaling pathway and specific cell surface HS structures, which in turn 
may help achieve the final control of the animal development.  Further study is needed to test 
the generality of this phenomenon in different cell types and in different species. 
Uronosyl 2-O-Sulfotransferase 
2-O-sulfation is the only sulfation that occurs on the uronic acid units (Figure 8), and 
it is observed in HS originating from all metazoans.  For instance, more than half of the 
IdoUA unit found it mouse embryo are 2-O-sulfated, while only a minute portion of the 
GlcUA are 2-O-sulfated (83).  In the adult tissues of Drosophila and C. elegans, about 20% 
and 30% uronic acid units are 2-O-sulfated (85).  2OST is capable of reacting with both 
GlcUA and IdoUA units, but prefers the latter under most conditions (Figure 12) (86). 
 
Figure 11: Schematic of 2-OST activity. 
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 Very much like C5-epi, 2OST has only one isoform in most species with the 
exception of fish.  2OST contains a type II transmembrane domain and is localized in the 
Golgi apparatus.  As described above, 2OST forms a complex with C5-epi in vivo, which is 
essential for the Golgi localization of C5-epi (50).  However, whether or not formation of this 
complex is critical for the Golgi localization of 2OST remains unclear.  The complex may 
also influence the substrate specificities of 2OST in HS biosynthesis in vivo.  One can 
imagine that when C5-epi and 2OST complex is formed, the majority of the resultant 
modification products would contain IdoUA2S.  When C5-epi is dissociated from 2OST, 
2OST may be allowed to generate GlcUA2S, and C5-epi is able to generate IdoUA without 
sulfation.  Thus, a possible role of C5-epi is to regulate the type of uronic acid that is 
subjected to 2OST modification.  Definitive demonstration of this possibility will require 
structural information from both 2OST and C5-epi, and the biological significance of the 
interaction should be tested in animal model systems. 
The HS 2OST knockout mouse suffered from neonatal death due to renal failure (87).  
The 2OST
-/-
 mice completely fail to form kidneys, show bilateral iris coloboma, and exhibit 
bone shortening and overmineralization.  All of these phenotypes are similar to those 
observed in the C5-epi
-/-
 mice, suggesting the essential roles of IdoUA2S in kidney, eye and 
skeletal development.  Surprisingly, 2OST
-/-
 mice apparently develop functional lungs, a 
sharp contrast to the Ndst-1 and C5-epi knockout mice.  This difference indicates that 2-O-
sulfation is not essential in lung development, but some IdoUA and GlcNS are required.  
Interestingly, close examination of the HS composition from 2OST
-/-
 mice reveals that while 
2-O-sulfated uronic acids are completely removed, the mice show elevated N-sulfation and 6-
O-sulfation of glucosamine units.  It has been proposed that the elevated sulfation at other 
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positions of HS may attenuate the adverse effect imposed by the ablation of 2-O-sulfation, 
thus disguising some physiological functions associated with 2-O-sulfation. 
The 2OST null mutant has been described in C. elegans as well (88).  Surprisingly, 
2OST deficient mutants are viable and fertile without any locomotory defect or embryonic 
paralysis as observed in perlecan deficient worms (89).  The phenotypes of 2OST null worms 
are only detectable in nervous system development by displaying axonal guidance and 
migration defects in a neuron-type specific manner.  These findings suggest that the 2-O-
sulfation of HS plays very specific roles in metazoan development.  These roles may vary in 
the developmental schemes of different species. 
Glucosaminyl 6-O-Sulfotransferase 
6-O-sulfation of glucosamine residues is a prevalent modification of HS.  The 
percentage of 6-O-sulfated disaccharide units represents 20 to 30% of total disaccharides in 
the HS from different species (83,85).  The 6-O-sulfation occurs most at the NS domain, 
generating a GlcNS6S moiety, but it can also occur at the NA domain, generating a 
GlcNAc6S moiety (90) (Figure 12).  It should be noted that 6-O-sulfation is the only type of 
sulfation that occurs at the NA domain as both 2OST and 3OSTs depend on the N-sulfation 
of glucosamine (Figure 8) (43,91). 
 
Figure 12: Schematic of 6-OST activity. 
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Three isoforms of 6OST have been identified in human and they exhibit 
approximately 60% identity (90). These isoforms have highly conserved sulfotransferase 
domains, while varying in both N- and C-termini.  Several in vitro substrate specificity 
assays suggest that 6OST isoforms have distinct substrate preferences (90,92).  6OST1 
appears to favor the IdoUA-GlcNS unit significantly more than the GlcUA-GlcNS unit, 
while 6OST2 prefers GlcUA-GlcNS over IdoUA-GlcNS, and 6OST3 has almost equal 
activities toward both disaccharide structures.  Three isoforms of 6OST are also present in 
other mammals and birds as well as amphibians, while invertebrates normally have only a 
single isoform of 6OST. 
Unlike the previously mentioned HS modification enzymes, a mouse knockout model 
for 6OST has not been reported.  Nonetheless, evidence from 6OST null Drosophila and C. 
elegans suggests that 6OST plays significant roles in animal developmental processes 
(77,88,93,94).  Knocking down 6OST in Drosophila disrupts the development of the tracheal 
system, their analog of the vertebrate vascular system.  Strong evidence indicates that this 
phenotype is directly related to the essential function of 6-O-sulfated HS in fibroblast growth 
factor (FGF) signaling (77).  Interestingly, C. elegans 6OST null mutants are viable and 
fertile, suggesting that 6-O-sulfation of HS is dispensable for worm FGF signaling.  
However, very specific axonal guidance defects were seen in a neuron-type specific manner.  
The effects of worm 6OST are believed to be related to several essential pathways in nervous 
system development, such as the Slit/Robo system and the Kal-1 system (88,93). 
A morphilino-mediated functional knockdown study targeting zebrafish 6OST, which 
has 58% identity to human 6OST1 and 6OST2, provided a glimpse of the essential functions 
of 6OST in vertebrate mrophogenesis (95).  The morpholino treatment decreased the overall 
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6-O-sulfation level by merely 20%, yet several obvious phenotypes were observed.  The 
most notable defects of 6OST knockdown zebrafish embryo were seen in somite 
development, as the embryo showed undifferentiated muscles and muscle degeneration.  
Additional defects caused by 6OST knockdown were also identified in the brain and the fins.  
It is now known that zebrafish have at least one other 6OST isoform, that is very homologous 
to human 6OST1 (81% identity), in addition to the 6OST that is knocked down in this study, 
which suggests that observed phenotypes may only represent a small fraction of the real 
impact of 6-O-sulfation of HS on zebrafish embryonic development. 
Glucosaminyl 3-O-Sulfotransferase  
3-O-sulfation of glucosamine unit is generally considered the last step in the HS 
biosynthetic pathway, and the rarest one.  3-O-sulfation occurs predominantly in the highly 
sulfated regions of HS, as 3OST modified disaccharide units often contain multiple sulfations 
(Figure 8) (96).  Modifications by 3-OST dictate unique functions of HS (Figure 13).  For 
instance, 3-O-sulfation is essential for the anticoagulant activity of HS, manifesting that this 
single modification increases the affinity to antithrombin by 18,000-fold (97).  As a result of 
extensive study, 3-O-sulfation of HS has been directly associated with many other biological 
processes such as viral infection (98), carcinogenesis (99), diurnal rhythm control (100) as 
well as lower organism morphogenesis (94).   
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Figure 13:  Substrate specificities of 3-OSTs.  R groups are either N-SO3 or NH2 groups of 
the glucosamine. 
 
 3-OST represents the most extended gene family among all HS sulfotransferases.  
Vertebrates generally contain seven isoforms, while invertebrates tend to have two.  The 
vertebrate 3-OSTs can be divided into two subgroups based on the homology of the 
sulfotransferase domain.  3-OST2, 3-OST3 (including 3A and 3B), 3-OST4 and 3-OST6 
form one subgroup, the so called 3-OST3-like subgroup, with higher than 70% identity; 
whereas 3-OST1 and 3-OST5 form another subgroup, the so called 3-OST1-like subgroup, 
with 53% of identity.  The 3-OST1-like and 3-OST3-like subgroups exhibit approximately 
45% identity in the sulfotransferase domain.  Two 3-OST isoforms, Hs3st-A and Hs3st-B, 
are identified in Drosophila (94).  Interestingly, Hs3st-A is more homologous to human 3-
OST1-like subgroup, while Hs3st-B is more homologous to 3OST3-like subgroup.  Similar 
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two 3-OST isoforms were found in C. elegans.  These observations suggest that it is likely 
that 3-OST diverged into two branches early in the evolution to perform separate functions, 
and both branches expanded in vertebrates to carry out more diverse and specific roles. 
 In comparison to the promiscuous substrate specificities of 6OSTs, members of 3-
OST family have distinctive substrate specificities.  3OST1 synthesizes a characteristic 
disaccharide unit with the structure of GlcUA-GlcNS3S±6S (Figure 8) (101), which is a 
critical modification step for synthesizing anticoagulant HS.  3OST2, 3OST3, 3OST4 and 
3OST6 all generate a characteristic disaccharide unit with a structure of IdoUA2S-GlcNS (or 
NH2)3S6S (Figure 13) (102-104), which is part of the structure of HS serving as an entry 
receptor for herpes simplex virus 1.  3OST5 is unique in that it enables to synthesize these 
two disaccharide units (105).  The distinct disaccharide units generated by 3-OST confer the 
functions of HS.   
Among seven isoforms of 3-OST, only 3-OST-1 has been knocked out in mice (106).  
The study was originally aimed to determine the effect of the level of anticoagulant HS on 
the blood coagulation process, provided that 3-OST-1 is a critical enzyme for synthesizing 
anticoagulant HS.  However, the 3-OST-1
-/-
 mice exhibit a surprisingly normal 
anticoagulation phenotype despite the fact the level of anticoagulant HS synthesis was 
reduced significantly in various organs.  The authors concluded that the anticoagulant HS is 
not a major hemostatic regulator regardless of the potent anticoagulant property of heparin 
drug.  Nevertheless, 3-OST-1
-/-
 mice exhibit a genetic background-specific postnatal 
lethality.  The cause of the lethality is unknown, yet is clearly distinct from the lethality 
caused by antithrombin
-/-
 mice.  This finding suggests that 3-OST-1 modification of HS plays 
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some profound roles in other biological processes although the details of this involvement 
remain unclear. 
 Studies in Drosophila provided the first direct evidence of the critical roles played by 
3OST in animal development (94).  When Drosophila Hs3st-B was silenced by RNAi 
treatment, several morphological defects were observed.  These included server rough eye 
phenotype, extra sensory bristles at multiple tissues and profound defects in wing 
morphology such as reduced wing size, abnormal wing veins and notching at the wing 
margin.  The phenotypic effects of Hs3st-B silencing have been related to Notch signaling 
directly, as Hs3st-B was show to influence the protein level of Notch (cell surface receptor in 
Notch signaling).  The exact role of Hs3st-B modified HS in the Notch signaling pathway 
remains to be determined. 
Section 5: Chemical and Enzymatic Synthesis of Heparan sulfate 
 The study of heparin has been limited due to the difficulty in its synthesis.  There 
have been two approaches to synthesizing these polysaccharides for study: chemical and 
enzymatic.  Chemical synthesis has been proven to be successful for oligosaccharides and 
strides have been made to make this synthesis easier and more diverse.  The enzymatic 
synthetic approach is now being exploited for the synthesis of polysaccharides. 
Chemical Synthesis 
 Chemical synthesis of oligosaccharides has been achieved by various laboratories.  
However, these oligosaccharides are usually simplistic in nature and do not demonstrate the 
versatility of known heparin structures.  To date, the most commonly known and used 
synthetic heparin is the anticoagulant pentasaccharide (107).  Difficulty in chemical synthesis 
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occurs in different ways.  Building an oligosaccharide backbone is difficult because you must 
maintain the stereochemistry of the glycosidic bonds.  Also, chemical sulfation is difficult to 
control.  Unwanted O-sulfations can arise (108-110). 
Chemoenzymatic Approach 
 The exploitation of the HS biosynthetic enzymes has been key in generating HS 
polysaccharides.  Using a combination of chemical and enzymatic synthesis has opened the 
possibility of creating a wider variety of HS polysaccharides.  One such tool utilized in 
chemoenzymatic synthesis is the PAPS regeneration system (Figure 14).  In this system, the 
sulfo group donor, PAPS, is constantly regenerated within the system to eliminate negative 
feedback and drive the reaction to completion.  For example, PAP is an inhibitor of the 
sulfotransferases, but the production of PAP can be decreased by adding PNPS (a new sulfo 
group donor) and aryl sulfotransferase IV (AST-IV) to the reaction.  In this regeneration 
system, PNPS becomes a sulfo donor to PAP, thus generating more PAPS for use by the 
heparan sulfate sulfotransferase of choice (111,112). 
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Figure 14: Schematic of the PAPS regeneration system.  PAPS is regenerated using PNPS 
as a donor.  The sulfate group is removed from PNPS and transferred to PAP via 
arylsulfotransferase IV.  The generated PAPS can then be used by the HS sulfotransferases 
for transfer of the sulfate group to the HS chain. 
  
Section 6: Structural Analysis of Heparan sulfate 
 Structural analysis of polysaccharides has proven to be a difficult task.  Currently, 
there are methods to analyze short oligosaccharides, such as, mass spectrometry and nuclear 
magnetic resonance (NMR).  Since HS polysaccharides are a heterogenous mixture, 
researchers have been able to elucidate structural characteristics of HS polysaccharides via 
disaccharide analysis.  Disaccharides can then be analyzed via high performance liquid 
chromatography (HPLC) techniques to determine the amount and ratios of the disaccharides 
yielded (113).   
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Heparin Lyase Degradation 
 The heparan sulfate lyases are which are able to cleave heparan sulfate 
polysaccharides down to disaccharides using β-elimination.  The use of lyases has become a 
popular tool to identify the composition of heparan sulfate polysaccharides.  There are three 
heparin lyases, named heparin lyase I, heparin lyase II and heparin lyase III and each has it‟s 
own substrate specificity (Figure 15).  Heparin lyase I cleaves at GlcNS(±6S)( ±3S)α(1 
→4)IdoA(±2S).  Heparin lyase II cleaves at either iduronic or glucuronic residues.  Heparin 
lyase III cleaves at GlcNAc or GlcNS that does not contain 6-O-sulfation (113).  Utilizing 
these enzymes singularly or in concert can determine which disaccharides will be yielded.  
Using this method, one can select for detection of different structural features.  These 
disaccharides can be detected at UV 232 nm due to the inclusion of a double bond at the C5 
position of the uronic residue.  However, the creation of this bond inhibits our ability to 
differentiate between a glucuronic and iduronic residue as the flexibility has been reduced.  
39 
 
 
Figure 15: Schematic of the substrate specificity of the heparin lyases. 
 
Nitrous Acid Degradation 
 Nitrous acid degradation is another powerful tool to elucidate the disaccharide 
composition of heparan sulfate polysaccharides.  Using nitrous acid, you can control which 
type of glycosidic bonds are broken by controlling the pH of the reaction.  Nitrous acid 
reduction maintains the stereochemistry of the C5 position in the uronic residue making it 
possible to differentiate between a glucuronic and iduronic residue (Figure 16)(114,115). 
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Figure 16: Schematic of low and high pH nitrous degradation.  R groups represent either 
–OSO3- or –H. 
 
Section 7:  Statement of Problem 
 The study of heparin and heparan sulfate function has grown vastly over the past 40 
years.  These structures have been implicated in various biological activities including, 
proliferaction, viral and bacterial infection and anticoagulation.  Study of the structure and 
activity relationship of HS is useful to tailoring these molecules for specific functions.  For 
instance, currently, HS-like structures are being studied for their ability to inhibit cancer 
(17,116).  The most significant structurally designed heparin is the anticoagulant 
pentassaccharide Arixtra (110).  To date, this is the only structurally defined heparin used 
41 
 
medically.  But, the cost of production of Arixtra is more than the cost of the production of 
heparin, thus, the use of heparin has remained popular in the hospital.  Medical 
administration of heparin can have its downfall.   Side-effects such as heparin-induced 
thrombocytopenia can arise, consequently providing the need for an even more biologically 
specific heparin.  The structure activity relationship of heparin structure has been limited due 
to the difficulty of synthesizing specific structures.  Different methods have been used to 
synthesize this class of polysaccaharides, but only a chemoenzymatic approach has had 
success.  In this thesis, I will present a method for not only generating a HS polysaccharide 
library via a chemoenzymatic approach, but I will use this method to study the SAR of these 
polysaccharides in order to generate structural classes specific for anticoagulation with a 
decreased effect in FGF-mediated cell proliferation and hypersensitivity activities. 
  
  
CHAPTER II: 
MATERIALS AND METHODS 
Agarose Gel Electrophoresis 
 A 1% agarose gel (in 0.5x TAE buffer) containing ethidium bromide (1 µL of 5 
mg/mL solution) was used to analyze PCR products and DNA plasmid constructs.  The gel 
was run at 120 mA and analyzed with UV light.    
SDS-PAGE Electrophoresis 
 For analysis of the HS biosynthetic enzymes, a 10% SDS-PAGE gel (Bio-Rad) was 
used.  For analysis of PF4 enzyme, a 12% Bis-Tris gel (Invitrogen) was used.  Samples 
analyzed via the SDS page gel were mixed with β-mercaptoethanol and loading dye and 
boiled at 100°C for 5 minutes before adding to lanes.  Samples analyzed via the Bis-Tris gel 
were mixed with a sample reducing agent and loading buffer before boiling them at 70°C for 
10 minutes.  The SDS gel was run using SDS buffer and the Bis-Tris gel was run using MES 
buffer (supplemented with an antioxidant agent immediately before running of the gel).  Both 
gels were run at 120mV for about 45-60 minutes.  Both gels were analyzed via staining. 
Transformation of Competent Cells 
 Add 1 µL of plasmid DNA (about 100 ng) to 50 µL of competent cells (origami B, 
origami B
chap
, BL21, or Bl21
star
).  Incubate on ice for 30 minutes.  Then, heat shock the 
reaction at 42°C for 45 seconds.  Incubate the cells again for 2 minutes on ice before adding 
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1 mL of LB broth.  Incubate these cells at 37°C for 2-4 hours while shaking at 220 rpm.  
Plate 100-100 µL of cells on LB plates containing the appropriate antibiotics and incubate 
the plate at 37°C overnight.  
Expression of HS Sulfotransferases in Origami B/OrigamiB
chap
 cell lines 
 Origami B (DE3) or Origami B
chap
 (Origami B cells that also express chaperonin
proteins GroEL/GroES) were transformed as previously described.   
Origami B (DE3) cells 
 A single colony was used to inoculate a 3mL starter culture comprised of LB broth 
containing 12.5 µg/mL tetracycline, 50 µg/mL carbenicillin (if the plasmid had this 
resistance), and 15 µg/mL kanamycin.  This starter culture was incubated at 37°C with 
shaking at 220 rpm overnight.  The following day, 750 µL of the starter culture was added to 
a 100 mL culture containing the appropriate antibiotics and incubated for another 3-4 hours.  
The cells were then cooled to 22°C after the OD600 reached between 0.6-0.8 and induced 
with isopropyl-β-D-galactopyranoside (IPTG) of final concentration 200 µM.  These cells 
were then shaken overnight at 22°C before harvesting. 
Origami B
chap
 cells 
 These cells were expressed using the aforementioned protocol for Origami B cells 
with a few minor additions.  Cultures were incubated with 3-4 antibiotics, 12.5 µg/mL 
tetracycline, 50 µg/mL carbenicillin (if the plasmid had this resistance), 15 µg/mL 
kanamycin, and 40 µg/mL chloramphenicol.  Also, in addition to IPTG during induction, the 
GroEL/GroES chaperone proteins were also induced using L-arabinose.  L-arabinose was 
added about 15 minutes prior to IPTG induction. 
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Expression of HS Sulfotransferases in BL21/BL21
star
 cell lines 
 BL21 and BL21star (BL21 cells with a mutation in RNase) were transformed as 
previously described.  Both cell lines were expressed as described above, however, antibiotic 
resistance solely depended upon the resistance of the plasmid.  These cells were induced with 
only IPTG. 
Nickel Sepharose Fast Flow Affinity Chromatography for His6-Tagged Proteins 
 Cells were harvested at 7000 rpm for 30 minutes.  The cell pellet was then 
resuspended in 25 mLs (per liter of culture) of Nickel Buffer A (25 mM Tris, 500 mM NaCl, 
30 mM imidazole, pH 7.5).  Once resuspended, the cells were sonicated in a 50 mL tube for 3 
x 45 seconds (duty cycle 50%, output 7) for lysing.  These cells were then pelleted at 10,000 
rpm for 30 minutes.  The cell lysate was then filtered via a 1.5 micron filter (Whatman) prior 
to loading to a pre-equilibrate 7 mL Nickel Sepharose 6 Fast Flow column (GE Healthcare) 
at a rate of 3 mL/min.  The column was then washed with 7 column volumes of Ni buffer A 
to remove all unbound sample.  Then the protein of interest was collected in 3 mL fractions 
following elution with Ni buffer B (25 mM Tris, 500 mM NaCl, 300 mM imidazole, pH 7.5) 
during a 4 column volume gradient length followed by a 60mL elution with 100%B.  The 
protein was typically eluted in 35-40 mL total volume.  
Amylose Affinity Chromatography for MBP Fusion Proteins 
 Cells were harvested as previously described.  The cell pellet was then resuspended in 
25 mLs (per liter of culture) of amylose Buffer A (25 mM Tris, 500 mM NaCl, pH 7.5).  
Once resuspended, the cells were sonicated in a 50mL tube for 3 x 45 seconds (duty cycle 
50%, output 7) for lysing.  These cells were then pelleted at 10,000rpm for 30 minutes.  The 
cell lysate was then filtered via a 1.5 micron filter (Whatman) prior to loading to a pre-
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equilibrated 10 mL Amylose column (New England Biolabs) at a rate of 2vmL/min.  The 
column was then washed with 10 column volumes of amylose buffer A to remove all 
unbound sample.  Then the protein of interest was collected in 3vmL fractions following 
elution with amylose buffer B (25 mM Tris, 500 mM NaCl, 30 mM maltose, pH 7.5) during 
a 3 column volume gradient length followed by a 40 mL elution with 100%B.  The protein 
was typically eluted in 20-25 mL total volume. 
Glutathione Sepharose 4 Fast Flow Affinity Chromatography for GST fusion Proteins 
 These cells were harvested as previously described.  The cell pellet was then 
resuspended in 25 mLs (per liter of culture) of GST Buffer A (20 mM NaH2PO4, 500 mM 
NaCl, pH 7.2).  Once resuspended, the cells were sonicated in a 50 mL tube for 3 x 45 
seconds (duty cycle 50%, output 7) for lysing.  These cells were then pelleted at 10,000 rpm 
for 30 minutes.  The cell lysate was then filtered via a 1.5 micron filter (Whatman) prior to 
loading to a pre-equilibrate 10 mL Glutathione Sepharose 4 Fast Flow column (GE 
Healthcare) at a rate of 2 mL/min.  The column was then washed with 10 column volumes of 
amylose buffer A to remove all unbound sample.  Then the protein of interest was collected 
in 3 mL fractions following elution with glutathione buffer B (20 mM NaH2PO4, 500 mM 
NaCl, 10 mM glutathione, pH 7.2) during a 3 column volume gradient length followed by a 
90 mL elution delay with 100%B.  The protein was typically eluted in 40-45 mL total 
volume. 
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Cloning and Purification of mPF4 
Design of Primers and Polymerase Chain Reaction (PCR) 
 The forward and reverse primers were designed to contain the cut sites in the plasmid 
of interest (Table 2). 
Table 2: Primers usd for murine Platelet Factor 4 Cloning 
Primer name Primer sequence 
mouse PF4 forward primer with 
EcoRI for pMalc2x/Tev 
ATATATAAGAATTCGCTGGTCCCGAAGAAAGC
GAT 
mouse PF4 reverse primer with 
HindIII for pMalc2x/Tev and 
PET32/TEV 
ATTAAATAAAGCTTTACCTAACTCTCCAGGATT
TTC 
mouse PF4 forward primer with 
NcoI for PET32/TEV 
ATTAATTACCATGGCGCTGGTCCCGAAGAAAG
CGATG 
 
The PCR reaction contained the following: 5 µL 10X Pfu buffer, 1 µL 10 mM dNTP mix 
(New England Biolabs), 50-100 ng plasmid DNA, 1.5 µL of forward and 1.5 µL of reverse 
primers (25 µM each), 1µL Pfu turbo DNA polymerase (Stratagene), and water to a final 
volume of 50 µL.  The PCR protocol followed is shown in Table 3. 
Table 3: PCR conditions for cloning of mPF4 
Step Number of Cycles Temperature (°C) Time 
Initialization 1 94 3 min 
Denaturing 16 94 1 min 
Annealing  52 1 min 
Elongation
 
 68 1 min/kilobase 
Final Elongation 1 68 1 hour 
 
Following PCR, a 10 µL aliquot was analyzed via agarose gel electrophoresis (described 
above).  After confirmation of the product, 10 µL of the PCR product was digested with Dpn 
I restriction enzyme (New England Biolabs) at 37°C for 1 hour.  Finally, a 5 µL aliquot of 
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the digested product was used for transformation into 50 µL of XL10 gold competent cells.  
These plasmids were then transformed into the following expression systems:  Origami B 
(DE3). BL21 and BL21
star
 cell lines. 
 Purification of mPF4 was completed in four steps, purification with an affinity 
column, cleavage of the tag, purification with the heparin column and finally purification 
with the Sephadex 75.  Each of these steps was performed as described below.   
TEV Cleavage 
 Affinity affinity column purification (as previously described), cleavage of mPF4 
with TEV was carried out at 4°C.  The milligram amount of TEV added to the reaction was 
1/25
th
 of the milligram amount of mPF4.  The reaction was rotated for 16-18 hours at 4°C. 
Heparin column 
 The heparin column was used to purify mPF4 from its cleaved tag.  Once the TEV 
cleavage reaction was complete, the reaction was spun at 5000rpm and filtered with a 1.5 
micron (Whatman) filter.  The filtered sample was loaded at 3 mL/min to a pre-equilibrated 
10 mL Heparin column (GE Healthcare).  The column was washed with 10 mL of heparin 
buffer A (500 mM NaCl, 20 mM Tris, pH 8).  PF4 was eluted into 2mL fractions during a 
gradient elution over 4 column volumes with heparin buffer B (2000 mM NaCl, 20 mM Tris, 
pH 8) and a delay of 40 mLs.  The protein typically eluted in 20-30 mLs. 
Hi-Load Superdex 75/200 Gel Filtration Chromatography 
 Gel filtration chromatography was used during mPF4 purification to remove any 
additional impurities and check the size of the protein to ensure it was forming a tetramer.  
The protein was concentrated to 5-10 mLs using an Amicon centrifugal concentrator.  The 
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concentrated protein was then injected into the 10 mL sample loop and loaded at 1 mL/min 
onto the pre-equilibrated (with 20 mM MOPS, 400 mM NaCl, pH 7) 100 mL Superdex 75 
Gel Filtration column.  The column was then washed with the buffer at 1mL/min while 
collecting 2 mL fractions.  Molecular mass standards (cytochrome c – 12.4 kDa, carbonic 
anhydrase – 29 kDa, BSA – 66 kDa, and β-amylase – 200 kDa) purchased from Sigma 
Aldrich were used to determine the protein peak of interest. 
Calculating the concentration of mPF4 
 The concentration of mPF4 was calculated using the amino acid analysis results 
received from the University of California at Davis molecular structure facility.  The 
concentration of the salt concentration of mPF4 was decreased to 100 mM NaCl and about 
100 ug of sample was sent for analysis.  Initial mPF4 concentration was determined by 
multiplying the concentration given by the UV detection at 280 by 5.  Amino acid results 
were used to determine the molar amount of each amino acid.  Tyrosine was used as the 
internal standard since there is only one per monomer.  The molar amount of tyrosine was 
used to calculate the molar amount of protein. 
Expression of HS Biosynthetic Enzymes 
 Expression of HS biosynthetic enzymes, including NST, epimerase, 2-OST, 6-OST-1, 
and 3-OST-1, was carried out in E. coli using methods established in our laboratory. The 
expression of 6-OST-3 was also carried out in E. coli. Briefly, the catalytic domain of mouse 
6-OST-3 (Pro121– Pro450) was cloned into a pMalc2x vector (New England BioLab) from a 
mouse brain Quick clone cDNA library (BD Biosciences). The expression was carried out in 
Origami-B cells (Novagen) carrying pGro7 (Takara, Japan) plasmid expressing chaperonin 
proteins GroEL and GroES of E. coli. Transformed cells were grown in 6 L LB medium 
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supplemented with 2 mg/mL glucose, 12.5 mg/mL tetracycline, 15 mg/mL kanamycin, 35 
mg/mL chloramphenicol, and 50 mg/mL carbenicillin at 37°C. When the A600 reached 0.4–
0.7, isopropyl-thiogalactopyranoside (0.15 mM) and L-arabinose (1 mg/mL) were added to 
induce the expression of 6-OST-3 and chaperonin proteins, respectively. The cells were 
allowed to shake overnight at 22°C. Purification was carried out with an amylose-agarose 
(New England BioLab) column by following the protocols provided by manufacturer. 
Purification of Heparosan 
 K5 capsular polysaccharide, or heparosan, is purified from E. coli containing the K5 
strain.  These cells are grown at 37°C for 16-18 hours.  Heparosan is purified from the cells 
after centrifugation at 7000 rpm.  The supernatant is collected, filtered and titrated to pH 5.  
This supernatant is then mixed at a 1:1 ratio with loading buffer (20 mM NaAcO, 50 mM 
NaCl, pH 5).  Heparosan is further purified via ion-exchange chromatography (DEAE 
purification).  After elution with high salt, the purified heparosan is ethanol precipitated with 
3:1 ethanol to heparosan.  Final purification is performed using ammonium sulfate 
precipitation.     
Deacetylation of Heparosan with NaOH 
 Forty milligrams of heparosan is lyophilized.  This sample was resuspended in 4 mL 
of 2000 mM NaOH and rotated at 68°C for another 3 hours.  This reaction was neutralized 
with 2000 mM HCl and dialyzed and lyophilized. 
Deacetylation of Heparosan with NDase II 
 In a 100 µL reaction, 1 µg of heparosan is incubated with 20 µL of NDase II (1 
mg/mL) and buffer containing 50mM MES (pH 6.5), 0.1% Triton X-100, 8 mM Mn
2+
.  This 
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reaction was incubated at 37°C for 1 hour.  The efficiency of this reaction was checked by 
the efficiency of a subsequent N-sulfation reaction. 
Chemical N-sulfation of Deacetylated Heparosan 
 Dissolve 2 mg of deacetylated K5 in 1 mL of water.  Add 0.1 M NaOH dropwise 
until the pH reaches between 9.5-10.  Calculate the number of free amine groups and 
multiply by 15 to get the amount of sulfur trioxide pyridine that needs to be added.  Add 
about 1/5
th
 of the amount of sulfur trioxide pyridine to the mixture.  Re-titrate the sample 
with 0.1 M NaOH to pH 9.5 after 30 minutes.  Then add another 1/5
th
 of the sulfur trioxide 
pyridine.  Repeat the procedure until all of the sulfur trioxide pyridine is added.  When the 
pH is stable at 9.5 for about an hour, dialyze the sample for 16 hours in 0.1 N ammonium 
bicarbonate buffer. 
N-acetylation Reaction of Deacetylated or N-sulfated Heparosan 
 About 72 pmols of lyophilized polysaccharide was dissolved in 20 µl of a solvent 
containing N,N-dimethylformamide and triethylamine (1:1, v/v) and 5 µl of acetic anhydride, 
and incubated on ice for 1 hr. Tris (20 ul of 50 mM) was then added and the reaction mixture 
was incubated on ice for an additional hour. The sample was then diluted with 10 volumes of 
water and dialyzed against 50 mM ammonium bicarbonate. 
Preparation of N-sulfo Heparosan 
 Heparosan was isolated from E. coli K5 strain by using a DEAE column, as described 
above.  The deacetylated heparosan was achieved under alkaline conditions (deacetylation 
via 2000 mM sodium hydroxide) as previously described. The deacetylated heparosan was 
incubated with purified NST and coupled with a PAPS regeneration system. Briefly, 2.5 mg 
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purified AST-IV was incubated with 40 mM PAP and 1 mM p-nitrophenol sulfate (PNPS) in 
40 mL 50 mM MES (pH 7.0), 1% Triton X-100, 1 mM MgCl2, and 1 mM MnCl2 at 25°C for 
15 min. The reaction mixture was mixed with N-sulfotransferase (10 mg), 5 mg deacetylated 
heparosan was added, and the mixture was rotated at 25°C for 24 hr. The N-sulfo heparosan 
was recovered by a DEAE column. The resultant product was subjected to a mixture of 
heparin lyases, followed by a disaccharide analysis to assess the level of N-sulfation. After 
two rounds of the modifications, the N-sulfation level reached 80% as determined by HPLC 
analysis. 
Preparation of N-sulfo Oligosaccharides 
 N-
35
S-labeled sulfo heparosan (1 mg, 1.5 x 10
6
 cpm) was mixed with 20 ng purified 
heparin lyase III in 1 mL 50 mM sodium phosphate (pH 7.0). The digestion lasted for 18 hr 
and was terminated by heating at 100°C for 2 min. The digested polysaccharide was resolved 
on a Bio- Gel P-10, which was eluted with a buffer containing 25 mM Tris and 1000 mM 
NaCl (pH 7.4) at a flow rate of 2 mL/hr. 
Preparation of Polysaccharides with Varying 6-O-sulfation 
 Polysaccharides with varying 6-O-sulfation were synthesized by varying the amount 
of N-sulfated heparosan added to the reaction.  0.5-4 µg of N-sulfated heparosan was added 
to a reaction containing MES/Triton X-100 buffer (to bring the volume to 100 µL), 20 µL of 
6-OST isoforms 1 and 3 each and a mixture of 100 µM cold PAPS (final concentration) 
mixed with hot (radiolabeled) PAP[
35
S]S.  These reactions were incubated at 37°C overnight 
and purified by DEAE chromatography.  
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Preparation of Polysaccharides with Varying N-sulfation 
 Polysaccharides with varying N-sulfation were synthesized by varying the amount of 
cold PAPS added to the reaction.  The reaction mixture consisted of 6 µL of 12.5 mg/mL of 
deacetylated heparosan.  The amount of PAPS ranged from 0.25 to 2 times the amount of 
unsubstituted N- groups of the glucosamine.  Fifty microliters of NST (1 mg/mL) was added 
to the reaction.  The reaction volume was brought to 1mL with MES/Triton X-100 buffer.  
These reactions were then incubated at 37°C overnight.  The following day, these samples 
were lyophilized and then N-acetylated using the aforementioned protocol.  They were then 
purified by DEAE chromatography. 
Modification of Polysaccharides 
 N-sulfo heparosan was prepared by incubating chemically deacetylated heparosan 
with purified NST and the components of the PAPS regeneration system described below. N-
sulfo heparosan (150 mg) was incubated with 
35
S-labeled PAPS (120 mM, 4.5 x 10
3
 
cpm/nmole) and the combination of epimerase (2.7 mg if included), 2-OST (8 mg if 
included), 6-OST-1 (1.2 mg if included), 6-OST-3 (1.4 mg if included), and 3-OST-1 (0.9 mg 
if included) in 50 mM MES and 1% Triton X-100 (pH 7.0). The reactions were incubated at 
37°C for 2 hrs with shaking. The resultant 
35
S-labeled polysaccharides were purified by 
DEAE chromatography.  
Modification of Oligosaccharides 
 To prepare the enzymatically modified oligosaccharides, the N-
35
S-labeled sulfo 
oligosaccharide substrates (1 mg, 1,500 cpm) were incubated with a mixture of 6-OST-1 (20 
mg), 6-OST-3 (20 mg), 3-OST-1 (10 mg), and [
35
S] PAPS (50 mM, 2.85x10
5
 cpm/nmole) in 
100 mL 50 mM MES and 1% Triton X-100. Alternatively, the oligosaccharide substrates (1 
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mg) were incubated with epimerase (7 mg) at 37°C for 30 min before they were incubated 
with a mixture of 2-OST (40 mg), 6-OST-1 (20 mg), 6-OST-3 (20 mg), and 3-OST-1 (10 
mg). The reactions were terminated by heating at 100°C for 2 min. 
PAPS Regeneration System 
 The reactions involved in the PAPS regeneration system are shown in Figure 14. N-
terminal (His)6-tagged AST-IV was expressed in E. coli and purified as described by Burkat 
and colleagues (111) at a yields 50 mg/l bacterial culture. 
DEAE Purification 
 400µL diethyl aminoethyl (DEAE) sephacel columns were pre-equilibrated with salt 
and UPAS buffer (3000 mM Urea, 150 mM NaCl, 0.0001% Triton-100, pH 4).  Samples 
were mixed with 2 x column volume of UPAS buffer and added to the DEAE column.  The 
columns were then washed with 2 mL of UPAS followed by a 1 mL wash with 250 mM 
NaCl buffer.  The samples were then eluted with 1 mL of 1 M NaCl.  
Heparin Lyase Degradation 
 Thirty micrograms of polysaccharide substrate is degraded using one or a 
combination of the heparin lyases.  Fifteen microliters of the lyases (1 mg/mL) of interest 
were added to the reaction.  The reaction is brought to 200µL with 50mM ammonium acetate 
buffer.  This reaction is incubated overnight at 37°C to yield disaccharides.  This reaction is 
completed with the inactivation of the enzymes via boiling at 100°C for 2 minutes. 
Low pH Nitrous Degradation 
 Samples were resuspended in 20 µL of water.  Forty microliters of the supernatant of 
1:1 (1 N (0.5 M) H2SO4:0.5 M Ba(NO2)2) was added and the solution was incubated on ice 
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for 30 minutes.  Twenty microliters of 7:3 (1 M Na2CO3:1 M NaHCO3) pH 9.5 was added to 
stop the reaction.  Twenty microliters of 0.5 sodium borohydride in 0.1 N sodium hydroxide 
was added and the solution was incubated at 50°C for 30 minutes.  The sample is then cooled 
to room temperature and 20 µL of 10N acetic acid is added to stop the reaction. 
Analyzation of Disaccharides 
 Degraded radiolabeled heparan sulfate samples are analyzed using reverse-phase ion 
pairing HPLC.  The disaccharides are resolved by a C18 reverse-phase column (0.46 x 25 
cm) (Vydac) under reverse-phase ion pairing HPLC conditions. The identities of the 
disaccharides were determined by coeluting with appropriate 
35
S-labeled disaccharide 
standards.  
Determination of the amount of polysaccharides 
 The amount of the synthetic polysaccharides was estimated by a colorimetric method 
with alcian as described (117); in this method, the standard curve was generated by using HS 
isolated from bovine kidney.  To measure the concentrations of heparosan, N-sulfo 
heparosan, and N-sulfo heparosan 6-O-sulfate, the polysaccharides were depolymerized to 
disaccharides by using a mixture of heparin lyases I, II, and III.  The amount of the resultant 
disaccharides was determined by co-eluting with disaccharide standards (from Seikagaku) on 
RPIP-HPLC as described above, by using UV 232 nm detection. 
Isothermal titration calorimetry with Artixa and PF4 
 Both Arixtra and PF4 were dialyzed into ITC phosphate buffer (NaCl, NaH2PO4, 
Na2HPO4, pH 7).  The concentration of PF4 needed for an ITC experiment was based on the 
possible KD.  The ligand concentration must be at least 7 times the PF4 concentration.  Using 
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a concentration of 0.02 mM mPF4 and 2.4 mM of Arixtra (a concentration difference of 
120x), the ITC experiment was conducted.  Each sample was degassed prior to the 
experiment.  Two milliliters of PF4 was added to the cell and 600 µL of Arixtra was titrated 
in.  KD was determined using the K value given by the program. 
Affinity Co-Electrophoresis 
 The dissociation constant (KD) of each sample and AT was determined by using 
affinity coelectrophoresis, an efficient method for determining the binding affinities of GAGs 
and proteins (118).  Approximately 4000–5000 cpm antithrombin-binding, 35S-labeled 
polysaccharide was loaded per lane; there were zones of AT at concentrations of 0, 8, 16, 60, 
and 120 nM. The gel was run at 400 mA for 2 hr, dried, and then analyzed on a 
PhosphoImager (Amersham Biosciences, Storm 860). The retardation coefficient was 
calculated at R = (M0 - M)/M, where M0 is the mobility of the polysaccharide through the 
zone without AT, and M is the mobility of the polysaccharide through each separation zone. 
The retardation coefficient was then plotted against the retardation coefficient divided by its 
respective concentration of AT. The slope of the line -1/KD.  This procedure was repeated 
using varying concentrations of either AT or PF4. 
AT-Affinity Assay       
 This assay is utilized to determine the percentage of a polysaccharide mixture that is 
able to bind its protein of interest.  This assay is used as a preliminary screen to establish 
whether or not different heparan sulfate species bound to AT.  Further analysis with ACE 
(described above) is utilized for determining these structure‟s binding affinity.  
Approximately 1x10
5
 cpm 
35
S-labeled compound was incubated with 5 mg human AT 
(Cutter Biological) in 50 mL binding buffer containing 10 mM Tris-HCl (pH 7.5), 150 mM 
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NaCl, 1 mM Mn
2+
, 1 mM Mg
2+
, 1 mM Ca
2+
, 10 mM dextran sulfate, 0.0004% Triton X-100, 
and 0.02% sodium azide for 30 min at room temperature. ConA-Sepharose (Sigma, 50 mL 
1:1 slurry) was then added, and the reaction was shaken at room temperature for 1 hr. The 
beads were then washed three times in 1 mL binding buffer, and the bound polysaccharide 
was eluted with 1 mL 1 M NaCl. 
Factor Xa and IIa Assays 
 Briefly, factor Xa (Enzyme Research Laboratories, South Bend, IN or Sigma) and 
thrombin (Sigma) were diluted to 1 U/mL and 8 U/mL, respectively, with PBS containing 1 
mg/mL BSA. AT was diluted with PBS containing 1 mg/mL BSA to give a stock solution at 
the concentration of 27 mM.  The chromogenic substrates S-2765 (for factor Xa assay) and 
S-2238 (for thrombin assay) were purchased from Diapharma and prepared at 1 mM with 
PBS. The synthesized polysaccharides or heparin was dissolved in a buffer containing 50 
mM Tris-HCl (pH 8.4), 7.5 mM Na2EDTA, and175mM NaCl at various concentrations (1–
10,000ng/mL). The reaction mixture, which consisted of 25 µl AT stock solution and 25 µl 
of the solution containing polysaccharide, was incubated at 37°C for 2 min. Factor Xa (25µl) 
or thrombin (25µl) was added. After incubating at 37°Cfor 4 min, 25 µl S-2765 or S-2238 
was added. The absorbance of the reaction mixture was measured at 405 nm continuously for 
10 min.  The absorbance values were plotted against the reaction time. The initial reaction 
rates as a function of concentration were used to calculate the IC50. 
FGF BaF3 Cell Assay 
 The BaF3 cells ectopically expressing FGFR1c have been described previously.  The 
BaF3 FGFR1c cells were maintained in RPMI 1640 media (Sigma, St. Louis, MO) 
supplemented with 10% fetal bovine serum, 0.5 ng/mL IL-3 (PeproTech, Inc., Rocky Hill, 
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NJ), 2 mM L-glutamine, penicillin (50 U/mL), and streptomycin (50 mg/mL), and 50 mM b-
mercaptoethanol. For mitogenic assays, BaF3 FGFR1c cells were washed three times with 
RPMI 1640 media to remove IL-3 and resuspended in the growth media lacking IL-3. About 
30,000 cells were plated per well in a 96-well plate in media containing various 
concentrations of heparin, compounds 1, 2, 7, and 8, and 2 nM FGF2 (PeproTech, Inc.) in a 
total volume of 200 mL. The cells were then incubated at 37°C for 40 hr. To each well, an 
additional 50 mL growth media containing 1 mCi [
3
H] thymidine was added. Cells were 
harvested after 4–5 hr by centrifugation. The incorporation of [3H] thymidine into the DNA 
was determined by scintillation counting. 
PF4 Filter Binding Assay 
 Three hundred microliter reactions were made containing varying concentrations of 
PF4 and 3000 counts of 
35
S-labeled polysaccharides in binding buffer comprised of 130 mM 
NaCl, 50 mM Tris, pH 7.3.  These reactions were incubated for 37°C for 30 minutes.  The 
substrate/PF4 complexes were then captured using pre-washed nitrocellulose filter paper.  
The percentage bound was determined by analyzing with the scintillation counter.
  
CHAPTER III: 
Using an Enzymatic Combinatorial Approach to Identify Anticoagulant Heparan 
Sulfate Structures 
Introduction  
 Heparan sulfate (HS) has been implicated in various biological activities including 
anticoagulation.  Heparin, a subset of HS polysaccharides, is a commonly used anticoagulant 
drug.  Synthesis of heparin and heparin-like drugs has been attempted both chemically to 
probe for structure and activity relationships; however, chemical synthesis longer than 
hexasaccharides has proven extremely difficult and an alternative method is needed.  This 
chapter will describe a chemoenzymatic method to generating anticoagulant heparan sulfate 
structures.  By utilizing biosynthetic enzymes used to modify HS chains, a library of heparan 
sulfate families was synthesized.  These families were then probed for anticoagulant activity 
via the anti-Xa and anti-IIa assays.  In addition to anticoagulant activity, these heparan 
sulfate families were also probed for cell proliferative activity via the BaF3 assay.  The 
methods described in this chapter provide a means for using a chemoenzymatic approach to 
generate heparan sulfate families with unique biological functions. 
Using An Enzymatic Approach To Create A Diverse Structure Library 
 Synthesis was begun using a capsular polysaccharide of the E. coli K5 strain, known 
as heparosan.   Heparosan is comprised of the disaccharide unit (-GlcUA-β1,4-GlcNAc-α1,4-
)n which is equivalent to non-sulfated and unepimerized HS (119).  In addition, heparosan 
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can be converted into anticoagulant HS by using HS biosynthetic enzymes (Figure 17) 
(108,120).  
 
Figure 17: Biosynthetic Pathway of HS.  The reactions catalyzed by HS biosynthetic 
enzymes.  The reaction sites at each modification step are circles.  The names and 
abbreviations for the saccharide units are displayed underneath the sugar unit. 
 
Because N-sulfation is critical for the subsequent O-sulfations and epimerization (121), we 
decided to prepare polysaccharides with different types of O-sulfation patterns by using N-
sulfo heparosan as starting material (Figure 18). Eight different polysaccharide families that 
differ by the type of sulfations, such as 2-O-, 3-O-, and 6-O-sulfations, as well as by the level 
of IdoUA residues, as illustrated in Figure 18, were prepared.   
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Figure 18: Synthetic Scheme of Polysaccharide Variants.  The steps involved in the 
synthesis of a library of HS-like polysaccharide families.  The enzymes used for each 
compound are shown in Table 2. 
 
The overall sulfation level among the products was between 0.9 and 1.4 nmoles O-sulfo 
groups per microgram of polysaccharide, namely, 0.39–0.61 O-sulfo groups per disaccharide 
unit, as measured based on the specific 
35
S radioactivity (Table 4). Family 6 was an 
exception because it contained only 3-O-sulfation, which is an inherently low-abundance 
sulfation type in the HS isolated from a natural source (31)  
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Table 4: Summary of the Synthetic Polysaccharides and the Results of Their Binding to 
Antithrombin 
Famillies Modification 
enzymes 
Structural 
features
a
 
O-[
35
S]sulfation 
level 
(nmoles /µg 
polysaccharide) 
Binding to 
antithrombin 
affinity 
column  (%)
b
 
Binding 
constant to 
antithrombin 
(KD) (nM)
c
 
1 2-OST, 6-
OST-1, 6-
OST-3 and 3-
OST-1 
No iduronic 
acid residue 
1.4 
 
51% 27 nM 
2 6-OST-1, 6-
OST-3 and 3-
OST-1 
No iduronic 
acid, no 2-
O-sulfation 
1.1 52% 57 nM 
3 3-OST-1 and 
2-OST 
No iduronic 
acid, no 6-
O-sulfation 
0.9 1.0% Not 
determined 
4 Epi, 2-OST 
and 3-OST-1 
No 6-O-
sulfation 
1.3 0.7% Not 
determined 
5 Epi, 2-OST, 
6-OST-1 and 
6-OST-3 
No 3-O-
sulfation 
1.5 0.6% Not 
determined 
6 Epi and 3-
OST-1 
No 2-O- 
and 6-O-
sulfations 
0.4 5.1% Not 
determined 
7 Epi, 6-OST-
1, 6-OST-3 
and 3-OST-1 
No 2-O-
sulfation 
1.3 29% 25 nM 
8 Epi, 6-OST-
1, 6-OST-3, 
3-OST-1 and 
2-OST 
Very 
similar to 
the HS 
isolated 
from tissues 
1.5 35% 29 nM 
Epi, C5-Epimerase;
 a 
These structural features are compared to heparin and HS isolated from 
natural sources. 
b 
The percentage of the 
35
S-labeled polysaccharide bound to the AT-affinity 
column was determined by incubating AT and the polysaccharides.  The complex of AT and 
polysaccharide was captured by using a ConA-agarose column. 
c 
The binding affinity of the 
polysaccharides and AT was determined by using affinity co-electrophoresis. 
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Antithrombin (AT) Binding of Structures 
Determining Binding Percentage via Antithrombin Affinity Column 
 Subjecting the synthetic polysaccharides to an antithrombin (AT)-affinity column, we 
found that a significant portion of families 1, 2, 7, and 8 bound to AT, while 3, 4, 5, and 6 
showed much less or no binding to AT (Table 4).  Binding percentage was determined by 
utilizing AT covalently linked to concanvalin A to capture the radiolabeled heparan sulfate 
polysaccharides.  The percentage of counts returned was used to determine the percentage of 
the polysaccharides that bound AT.  We noted that 1, 2, 7 and 8 all carry 3-O- and 6-O-sulfo 
groups, while 3, 4, 5, and 6 either lacked 3-O-sulfo or 6-O-sulfo groups. Thus, we concluded 
that both 3-O-sulfation and 6-O-sulfation of the glucosamine unit are critical for binding to 
AT. In addition, 2-O-sulfation of IdoUA is not essential, provided that 7 binds to AT. These 
conclusions are largely consistent with previously published results of chemically 
synthesized pentasaccharides (97) as well as enzymatically synthesized polysaccharides 
(49,122). 
KD Determination via Affinity Co-Electrophoresis 
 For polysaccharides, affinity co-electrophoresis (ACE) is utilized to determine their 
binding affinities to proteins (Figure 19).  An ACE gel was run to determine each family‟s 
binding affinity to AT.  Scatchard plot analysis determined the binding constants (or KDs) of 
the synthetic polysaccharides and AT to be in the range of 27–57 nM (Table 4), which are 
very similar to that of previously characterized anticoagulant HS (120). 
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Figure 19:  ACE gel and Scatchard Plot for Family 2 Bound to AT.  The left panel shows 
the ACE gel run with [AT] ranging from 0-120 nM.  4000 radiolabeled counts of family 2 
were added to each lane.  The right panel displays the Scatchard plot analysis for the ACE 
gel data.  The migration distance divided by the concentration of AT was plotted versus the 
migration distance and the binding affinity was determined as -1/slope. 
 
Anticoagulant Activity Determined Via Anti-Xa and Anti-IIa Assays 
 The chemoenzyzmatically synthesized polysaccharides displayed excellent 
anticoagulant activity, as measured by anti-Xa and anti-IIa activities (Table 5).  The IC50 
values of families 1, 2, 7, and 8 for Xa are 2- to 2.5-fold higher than that of unfractionated 
heparin, while they are about 2-fold lower than that of Lovenox, a low-molecular weight 
heparin drug manufactured by Aventis.  A similar trend was observed for the anti-IIa activity 
of these families. The N-sulfo heparosan 6-O-sulfate was used as a negative control and 
showed no inhibitory effect on the activity of Xa and IIa. 
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Table 5:  Anti-Xa and Anti-IIa activities of the biosynthetic polysaccharides. 
Families Anti-Xa activity, IC50 
(ng/mL) 
Anti-IIa activity, IC50 
(ng/mL) 
Heparin 25 8 
1 50 18 
2 50 20 
7 45 16 
8 40 15 
N-sulfo heparosan 
6-O-sulfate
a
 
>5,000 >3,000 
Lovenox
b
 90 50 
a
 The synthesis of N-sulfo heparosan 6-O-sulfate is displayed in Figure 19. 
b
 Lovenox was 
purchased from a local pharmacy. 
 
Structural Analysis of Anticoagulant Heparan sulfate Structures 
 Among the synthesized AT-binding polysaccharides, family 2 has the simplest 
structure because it should contain neither IdoUA nor 2-O-sulfo groups. To further elucidate 
the structure of the synthesized polysaccharides beyond knowing the types of sulfation and 
the overall amount of sulfation per picomole, we conducted the disaccharide analysis of 
family 2 and compared it to the disaccharide composition of family 8.  The resultant 
disaccharides were resolved on reverse-phase ion pairing (RPIP) HPLC (Figure 20).  This 
disaccharide analysis determined the types and ratios of disaccharides present in each 
heparan sulfate family.  Indeed, six disaccharides were observed in family 8, while only three 
disaccharides were observed in family 2.
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Figure 20:  RPIP-HPLC Chromatograms of the Disaccharide Analysis of Families 8 
and 2.  (A and B) The 
35
S-labeled polysaccharides were degraded by nitrous acid at pH 1.5, 
followed by sodium borohydride reduction. The resultant 
35
S-labeled disaccharides were 
desalted on a BioGel P-2 column, and then resolved by reverse-phase ion pairing HPLC 
chromatography. The elution positions were identified by coeluting with 
35
S-labeled or 
3
H-
labeled disaccharide standards; 1 represents GlcUA-AnMan3S, 2 represents IdoUA2S-
AnMan, 3 represents GlcUA-AnMan6S, 4 represents IdoUA-AnMan6S, 5 represents IdoUA-
AnMan3S6S, 6 represents GlcUA-AnMan3S6S, and 7 represents IdoUA2S-AnMan6S.  
 
 
Family 8 
Family 2 
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In addition, we noted that the ratio of the three disaccharides in 2, including GlcUA-
AnMan3S, GlcUAAnMan6S, and GlcUA-AnMan3S6S, is about 1:2:1 (Table 6), suggesting 
that this polysaccharide consists of a repeating tetrasaccharide unit with a structure of  
-GlcUAGlcNS6S-GlcUA-GlcNS3S ± 6S-. The results from disaccharide analysis also 
concluded that the IdoUA residue is not important for the polysaccharide to bind to AT. 
 
Table 6:  Compositional analysis of family 2 and family 8 
Disaccharides Family 2 
(mol/mol %) 
Family 8 
(mol/mol %) 
GlcUA-AnMan3S 24.7% N.D.* 
IdoUA2S-AnMan N.D. 35.9% 
GlcUA-AnMan6S 48.8% 23.3% 
IdoUA-AnMan6S N.D. 15.9% 
IdoUA-AnMan3S6S N.D. 2.2% 
GlcUA-AnMan3S6S 26.2% 8.9% 
IdoUA2S-AnMan6S N.D. 13.4% 
*Not detectable 
 
Large Scale Preparation of Recomparin 
 Due to the excellent activity and low structural heterogeneity of family 2, renamed 
Recomparin for “recombinant heparin”, we conducted its synthesis in miligram scale instead 
of microgram scale.  We repeated the synthesis of 2 from deacetylated heparosan by using 
sequential modifications with N-sulfotransferase (NST), 6-OST-1, 6-OST-3, and 3-OST-1 as 
described in Figure 21.   
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Figure 21: Synthetic scheme of Recomparin. The components involved in the PAPS 
regeneration system are boxed.  AST-IV represents arylsulfotransferase IV, and PAP 
represents 3‟-phosphoadenosine 5‟phosphate. 
 
 In this synthesis, we employed a 3‟-phosphoadenosine 5‟-phosphosulfate (PAPS) 
regeneration system that used p-nitrophenol sulfate (PNPS) as a sulfo donor in place of 
PAPS; this substitution potentially reduces the cost of the synthesis by more than 1000-fold 
and ensures a sufficient amount of sulfo donor is present (Figure 14)  (111,112). 
Disaccharide analysis on the intermediate compounds, including N-sulfo heparosan and N-
sulfo heparosan 6-O-sulfate, revealed that N-sulfation reached 75.6% and that 6-O-sulfation 
reached 85% (Table 7).  
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Table 7:  Summary of the disaccharide analysis of N-sulfo heparosan 6-sulfate 
Disaccharides N-sulfo heparosan 
(mol/mol %) 
N-sulfo heparosan 6-O-sulfate 
(mol/mol %) 
ΔUA-GlcNAc 24.4% 4.6% 
ΔUA-GlcNS 75.6% 10.4% 
ΔUA-GlcNAc6S N.D. 14.6% 
ΔUA-GlcNS6S N.D. 70.4% 
 
The 3-O sulfation carried out by 3-OST-1 went to about 90% completion, and it was 
estimated to be 0.5 3-O-sulfo groups/ disaccharide based on the modification with 
35
S-
labeled PAPS.  In each enzymatic step, the yield of modified polysaccharide obtained was 
about 50-75%, therefore, the overall yield of recomparin from 8mg of starting material was 
about 25% after 3 steps (Figure 20).The final product showed anti-Xa activity at the IC50 
value of 25 ng/mL, which is very close to the value of heparin (19 ng/mL) (Figure 22). Taken 
together, our results show that the enzyme-based approach is fully capable of synthesizing 
milligram amounts of this anticoagulant polysaccharide.   
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Figure 22:  Inhibition effects of heparin and recomparin on Xa activity.  Heparin and 
recomparin were incubated with AT (20 ug/mL) factor Xa (10 U/mL) and bovine serum 
albumin (100 µg/mL) in 20mM sodium phosphate and 150 mM NaCl pH 7.2, and 1 mM S-
2765 chromogenic Xa substrate.  This substrate acts as a peptide and in the absence of AT 
and heparin, it can be cleaved by factor Xa producing UV absorbance at 405 nm. The activity 
of Xa was determined by the rate of the increase of the absorbance at 405 nm.  The activity 
without polysaccharide was defined at 100%.  Each data point represents the average of two 
determinations.  Error bars indicate the range. 
 
AT Binding of Heparan sulfate Structures is Size Dependent 
 The fact that family 2, Recomparin, exhibits high binding affinity to AT and strong 
anticoagulant activity appeared to be contradictory to previously published results. The 
IdoUA residue has been implicated to be essential for the binding to AT because it provides 
conformational flexibility (110). In the antithrombin binding pentasaccharide, the IdoUA 
residue exists in either a chair (
1
C4) or a skew boat (
2
S0) conformation (110).  Furthermore, 
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the unique skew boat (
2
S0) of IdoUA2S in a synthetic pentasaccharide was proved to be 
essential for the binding to AT (123).  We believe that the degree to which conformational 
flexibility is necessary for AT-binding affinity is size dependent. To test this hypothesis, we 
compared the AT-binding oligosaccharides‟ synthetic efficiency by using a mixture of 
enzymes with or without the capability of synthesizing IdoUA2S. In one preparation, the 
oligosaccharides (for the synthesis of oligosaccharides without the IdoUA2S residue) were 
incubated with a mixture of enzymes containing 6-OST-1, 6-OST-3, and 3-OST-1. In another 
preparation, the oligosaccharides (for the synthesis of oligosaccharides with the IdoUA2S 
residue) were incubated with a mixture of enzymes containing epimerase and 2-OST as well 
as 6-OST- 1, 6-OST-3, and 3-OST-1. The oligosaccharide substrates with structures of ΔUA-
(GlcNS-GlcUA)n-GlcNS-, where n = 0, 1, 2, 3, 4, and ≥ 5 (for partially digested samples), 
were prepared by subjecting N-sulfo heparosan to partial depolymerization with heparin 
lyase III, followed by fractionation on gel permeation chromatography (Figure 23). 
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Figure 23:  Elution profiles of N-[
35
S]sulfo heparosan oligosaccharides on BioGel P-10.  
Low specific [
35
S] radioactively labeled N-[
35
S]sulfo heparosan (1.5x10
6
 cp/mg) was 
prepared by incubating deacetylated heparosan, purified NSG and [
35
S]PAPS.  The material 
(1 mg) was digested with 20 ng of purified heparin lyase III overnight.  The products were 
fractionated on a BioGel P-10 column, which was eluted with a buffer containing 25 mM 
Tris, 1000 mM NaCl, pH 7.4.  The fractions were monitored by both radioactivity and UV 
232 nm.  The fractions containing the oligosaccharides with the desired size were pooled for 
further analysis. 
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After the modifications, the AT-binding, 
35
S-labeled oligosaccharides were captured by the 
AT-affinity column, and the data are shown in Figure 24.  This AT-affinity column assay is 
utilized as a preliminary screen to demonstrate whether or not an oligosaccharide sample was 
able to bind AT.   
 
Figure 24:  Enzymatic Synthesis of AT-Binding Oligosaccharides.  The oligosaccharide 
substrates (1 µg) or the full-length N-sulfo hepar+osan (1 µg) were incubated with a mixture 
of enzymes, including 6-OST-1 (20 µg), 6-OST-3 (20 µg), 3-OST-1 (10 µg), and 
35
S –
labeled PAPS (30 µM, 285,000 cpm/nmol) at 37°C for 2 hr.  Alternatively, the 
oligosaccharides (1 µg) or full-length heparosan (1 µg) were preincubated with epimerase (8 
µg) at 37°C for 30 min, followed by incubation with a mixture of 6-OST-1 (20 µg), 6-OST-3 
(20 µg), 2-OST (40 µg), and 3-OST-1 (10 µg) in the presence of 
35
S-labeled PAPS.  The 
resultant 
35
S-labeled oligosaccharides were incubated with AT, and the complex of AT and 
35
S-labeled oligosaccharides was captured by a ConA-agarose column.  The amount of 
35
S-
labeled products with full-length N-sulfo heparosan was defined to be 100%. 
 
In the absence of epimerase and 2-OST, 
35
S-labeled octa- and decasaccharides showed 
substantial binding to AT, while 
35
S-labeled hexasaccharide showed a very low yield (Figure 
24). In contrast, when using the same oligosaccharide substrates in the presence of epimerase 
and 2-OST, 
35
S-labeled hexasaccharides displayed significant binding to AT. We noted that 
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the amount of AT-binding hexasaccharides and octasaccharides is about 4- to 5-fold higher 
than when the substrates were modified with a mixture of enzymes containing epimerase and 
2- OST. These results suggest that the contribution of the IdoUA2S to the oligosaccharide‟s 
ability to bind AT-binding may be less essential when the size of the oligosaccharides is 
larger than an octasaccharide. 
Newly Synthesized Polysaccharides Do Not Exhibit Proliferative Activity 
 Heparin and HS form a ternary complex with fibroblast growth factors (FGFs) and 
fibroblast growth factor receptors (FGFRs) to stimulate cell proliferation; however, this 
interaction clearly is not related to the anticoagulant activity of HS. Here, we tested whether 
the synthetic polysaccharides permit the separation of the anticoagulant activity and cell 
proliferation activity by using a BaF3 cell model system.  Baf3 cells originate from a murine 
lymphoid cell line (124).  The BaF3 cells overexpressing FGFR1 normally depend on 
interleukin 3 (IL-3) for growth. In the absence of IL-3, cell proliferation depends on the 
addition of both FGF and heparin or HS (125). The cells receiving heparin and family 8 
showed an increase in [
3
H] thymidine incorporation (Figure 25).   
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Figure 25:  The Effect of the Synthetic Polysaccharides on FGF2-Dependent BaF3 
FGFR1c Cell Proliferation.  BaF3 FGFR1c cells were seeded in 96-well plates with 2 nM 
FGF2 for control and 2nM FGF2 plus various concentrations of synthetic polysaccharides 
and heparin.  Cells were cultured for 40 hr, followed by incubation in the media containing 
[
3
H] thymidine for 4 hr.  The cellular proliferation was determined by [
3
H] thymidine 
incorporation into the DNA. 
 
Family 8 stimulated BaF3 cell growth to a lesser extent than heparin since its structure is 
closer to HS than heparin (112).  It should also be noted that family 8 was comprised of all of 
the possible sulfation modifications in addition to epimerization about the carbon 5 position.  
We also found that family 1 showed modest activity in stimulating cell proliferation.  
Families 2 and 7 had no detectable activity in stimulating cell proliferation, suggesting that 
we have successfully separated the anticoagulant activity and cell proliferation activity by 
removing IdoUA2S and IdoUA residues from the polysaccharide. 
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Conclusions 
 In this chapter, we reported an enzyme-based combinatorial approach to synthesize 
the polysaccharides with different sulfation patterns (Figure 18).  Our method permits the 
synthesis of polysaccharides that are restricted by certain types of sulfations due to the high 
substrate specificities of the sulfotransferases.  More importantly, this approach permits the 
synthesis of biologically active polysaccharides that may mimic the action of HS under 
physiological conditions.   From the products, we discovered that polysaccharides without 
the IdoUA residue displayed strong binding affinity to antithrombin and high anti-Xa and 
anti-IIa activities.  Further, these polysaccharides have no activity in promoting cell 
proliferation, thus providing evidence for the synthesis of a functionally specific 
anticoagulant polysaccharide.  Chemical synthesis of the IdoUA residue requires ten steps 
(126).  Although the synthesis of IdoUA can be achieved by epimerase, the product contains 
a mixture of IdoUA and GlcUA because the reaction catalyzed by epimerase is reversible 
(127).  Consequently, the product has greater structural heterogeneity, increasing the 
untoward effects of an anticoagulant drug. Anticoagulant polysaccharide without the IdoUA 
residues could decrease the structural heterogeneity and reduce the complexity in the 
synthesis of HS-based anticoagulant drugs.  
 
  
CHAPTER IV: 
Identifying Anticoagulant Heparan Sulfate Structures with a Decreased Affinity for 
Platelet Factor 4 (PF4) 
Introduction 
 Heparin, a specified form of HS, is a marketed anticoagulant drug that has been 
shown to elicit side-effects upon its administration.  The most complicated side-effect of 
heparin administration is heparin-induced thrombocytopenia (HIT) which occurs in about 2-
5% of patients receiving heparin.  HIT is an immune-mediated response initiated by the 
charge-mediated interaction of platelet factor 4 (PF4) and heparin.  Two problems arise in the 
study of this interaction: one, insufficient purification methods of PF4 and two, inability to 
fully study the structure activity relationship of the effects of heparin‟s sulfation on PF4 
binding.  Decreasing the size of the polysaccharide into oligosaccharides as well as 
chemically synthesizing specific biological structures have been methods utilized to address 
this problem.  However, none has successfully eliminated the possibility of HIT.  However, 
modulation of the highly negative charge of heparin polysaccharides could be key to 
diminishing this interaction.  Previously, we have been able to generate different families of 
heparan sulfate which maintain anticoagulant activity using a chemoenzymatic approach 
(128).  This chapter will describe a method for producing PF4 in large quantities for study as 
well as the synthesis of species of heparins with lower affinity for PF4 while maintaining 
anticoagulant activity. 
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Section 1:  Purification and Characterization of Murine Platelet Factor 4 
Cloning and Expression of Two mPF4 Fusion Proteins 
 Platelet Factor 4 (PF4) is a tetramer comprised of four identical 70 amino acid 
subunits (24).  Purification of PF4 for scientific studies has mainly been done via human 
platelets or recombinant protein purification.  However, this could be costly for large scale 
testing and variability between sources and batches becomes an issue.  We chose a murine 
PF4 (mPF4) sequence for our cloning which was obtained from OpenBiosystems.  The 
sequence used is shown in the table below (Table 8). 
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Table 8: Table of Murine Platelet Factor 4 constructs. 
 Vector Sequence Cell Lines 
Used for 
Expression 
Murine 
Platelet 
Factor 4 
(mPF4) 
Not applicable MSVAAVFRGLRPSPELLLLGLLFLPA 
VVAVTSAGPEESDGDLSCVCKTISSGIH 
LKHITSLEVIKAGRHCAVPQLIATLKNG 
RKICLDRQAPLYKKVIKKILES 
Not 
applicable 
Cleaved 
Maltose 
Binding 
mPF4 
pMALc2x/TEV GEPEAGPEESDGDLSCVCVKTISSGIH 
LKHITSLEVIKAGRHCAVPQLIATLKN 
GRKICLDR QAPLYKKIVIK KILES 
Origami B 
Cleaved 
Thioredoxin 
mPF4 
pET32/TEV GSRHGAGPEESDG DLSCVCKTISSGIH 
LKHITSLEVIKAGRHCAVPQLIATLKN 
GRKICLDR QAPLYKKVIK KILES 
BL21, BL21 
star 
The amino acids bolded in blue are part of the signaling sequence.  They were not included in 
the protein products.  The amino acids bolded in red are additional residues added to the 
mPF4 sequence after cleavage of the affinity tag. 
 
Tobacco etch virus (TEV) cleavage 
 A TEV cleavage site was engineered into each protein construct in order to create the 
ability to cleave our protein of interest, mPF4, from its corresponding affinity tag.  Tobacco 
etch virus recognizes the sequence E-N-L-Y-F-Q-S or more generally E-Xaa-Xaa-Y-Xaa-Q-
S/G.  Cleavage occurs between the Q and the S or G of the sequence (129,130).  By utilizing 
this cleavage site, we were able to remove the affinity tags of our proteins without adding too 
many additional residues to the protein. 
Maltose binding protein-fusion mPF4 (MBP-mPF4) 
 Cloning of the maltose binding fusion protein was performed using the pMAL-
c2x/TEV vector.  This vector sequence contains the TEV (Tobacco Etch Virus) cleavable 
sequence E-N-L-Y-F-Q which was used for removal of the MBP tag from the protein.  After 
cleavage, the protein sequence for the purified mPF4 was GlyGluPheAGPEESDG 
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DLSCVCVKTI  SSGIHLKHIT SLEVIKAGRH CAVPQLIATL KNGRKICLDR 
QAPLYKKVIK  KILES.  The first three amino acids listed (GlyGluPhe) were additional 
amino acids added to the sequence after cleavage of the MBP tag. 
 Expression of this sequence was performed in both BL21 and BL21 star cells.  In 
general purification was performed using three columns, the amylose affinity column, the 
heparin column and the Sepahadex 75 gel permeation chromatography column.  The 
optimization of this protocol is described in a later section.   
Thioredoxin-fusion mPF4 protein (TRX-mPF4) 
 Cloning of the thioredoxin (TRX) fusion protein was performed using the pET32b 
vector also containing a TEV site.  This vector sequence contains a His6 tag as well as the 
TEV cleavable sequence E-N-L-Y-F-Q-G which was used for removal of the TRX tag from 
the protein.  After cleavage, the protein sequence for the purified mPF4 was 
GLYSERARGHISGLYAGPEESDG DLSCVCVKTI SSGIHLKHITSLEVIKAGRH 
CAVPQLIATL KNGRKICLDR QAPLYKKVIKKILES.  The first five amino acids listed 
(GlySerArgHisGly) were additional amino acids added to the sequence post cleavage of the 
TRX tag. 
 Expression of this protein was performed in origami B, BL21 and Bl21 star cells.  In 
general purification was performed using three columns, the nickel affinity column, the 
heparin column and the Sepahadex 75 gel permeation chromatography column.  The 
optimization of this protocol is described in a later section.   
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Optimization of Murine Platelet Factor 4 (mPF4) Purification 
 Affinity column purification of each fusion protein was the same as described in 
Chapter 2 for the sulfotransferases.  However, purification past this point was optimized via 
various means.  TEV tag cleavage underwent a few trials by altering the amount of TEV 
added to each reaction.  TEV cleavage in general was an overnight process and the amount of 
TEV protein added to a reaction was based upon the amount of protein purified from the 
affinity column.  TEV cleavage occurred immediately following affinity column purification 
to ensure full removal of the tag.  After each purification step, an aliquoted sample was saved 
for PAGE gel electrophoresis (Figure 26).  Figure 26 depicts the purification of Trx-mPF4 in 
BL21 and BL21 star cell lines.  A NuPage 12% Bis-Tris gel purchased from Invitrogen was 
used for PAGE analysis.
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Figure 26: Purification of mPF4.  Gel representation of mPF4 purity.  Depicted are 12% 
Bis-Tris Gels.  Box a surrounds the band representing the uncleaved Trx-mPF4.  Box b 
surround the cleaved tag.  Box c surrounds the purified PF4 following heparin column 
purification
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 Murine platelet factor 4 was purified under a series of conditions.  Although each 
combination of conditions (Table 8) yielded mPF4, the most optimal cell line and tag was 
BL21 star and the thioredoxin tag.  Although the amount of protein generated from the MBP 
tagged protein was much higher than that of the thioredoxin tagged protein, after cleavage of 
the tag, the MBP originated protein precipitated while the thioredoxin tagged protein 
remained stable.  The amount of TEV protease used to remove the tag from the protein was 
based upon the amount of uncleaved protein.  The best condition for cleavage was an 
overnight reaction at 4°C between tagged protein and TEV at 1/25
th
 of the concentration of 
tagged protein.  Following cleavage, the protein was purified from the tag via the heparin 
column which yielded a pure protein.  Initially, this pure protein was then run over a sizing 
column to ensure the mPF4 was tetrameric.  This was confirmed using the Sephadex 75 and 
comparing mPF4‟s elution with standards (data not shown). 
Determination of Protein Product 
 Protein purity was identified using page gel analysis. However, further confirmation 
of identity and purity of our protein product was performed using amino acid compositional 
analysis and mass spectrometry analysis.  Amino acid compositional analysis and mass 
spectrometry of these proteins was performed at the Molecular Structure Facility at the 
University of California at Davis.   
Compositional analysis via Amino Acid Analysis 
 Since our mPF4 was comprised of 70 amino acid monomers that only contained one 
amino acid, tyrosine, that could be detected by UV for protein concentration, we reconfirmed 
our protein confirmation by using amino acid analysis (AAA) (See appendix, Figure A1).  
The AAA spectrum provided the molar amount of each amino acid present in our protein and 
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when compared to our sequence provided the molar amount of protein.  The ratio of the 
molar amount of protein provided by AAA was compared to that of the molar amount 
provided by UV absorption at 280 nm.  This ratio was used for preliminary determination of 
mPF4 concentration of subsequent batches until they could be confirmed by AAA. 
Matrix assisted laser desorption/ionization (MALDI) Mass Spectometry 
 MALDI-MS was used to also confirm the identity of our mPF4.  This method 
denoted the purity of our mPF4 samples as only one major peak was observed (Appendix 
Figure A2).  This MALDI spectrum indicates the size of our MBP fusion protein derived 
mPF4 monomer to be 8264.32 Da which was very close to the calculated molecular weight 
of 8256.74 Da.  A similar spectrum was obtained for the TRX fusion protein shown in 
Appendix Figure A3. 
KD determination between PF4 and heparin 
 To ensure that the mPF4 we obtained was functionally active, we tested the binding 
affinity for our mPF4 with Arixtra, a commercially available anticoagulant pentasaccharide, 
and heparin.  Our three methods for detection were isothermal titration calorimetry, dot blot 
analysis and affinity co-electrophoresis. 
Isothermal Titration Calorimetry (ITC) 
 Isothermal titration calorimetry (ITC) was used to determine the binding affinity of 
both Lovenox, a low molecular weight heparin, and Arixtra, an anticoagulant 
pentasaccharide, with mPF4 (Figure 27).  Based on the crystal structure of mPF4, I assumed 
that it contained two potential sites as shown in Figure 2.   Assuming that mPF4 has two 
potential binding sites, the KD of mPF4 (from MBP fusion protein) to Lovenox was 3.6 µM 
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and the KD of mPF4 (from thioredoxin fusion protein) to Arixtra was calculated to be 0.1 
mM.  The KD determined by the binding between Lovenox and mPF4 was unreliable 
however, due to precipitation caused by their interaction.  With the binding of Arixtra and 
PF4, I expected the binding affinity to decrease due to shorter length of the oligosaccharide, 
as there were less potential positions for interaction between the ligand and protein (131). 
 85 
 
0 2 4 6 8 10 12 14
-2
0-0.55
-0.50
-0.45
-0.40
-0.35
-0.30
-0.25
-0.20
-0.15
-0.10
-0.05
0.00
0.05
-20 0 20 40 60 80 100 120 140 160 180 200
Time (min)
µ
c
a
l/
s
e
c
Molar Ratio
k
c
a
l/
m
o
le
 o
f 
in
je
c
ta
n
t
 
Figure 27: ITC chromatogram for PF4 and Arixtra.  0.02mM of mPF4 was titrated with 
2.4mM of Arixtra. 
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Dot blot analysis 
 Dot blot analysis was used to determine the binding affinity of a mixture of 
radiolabeled ([
35
S] heparin at the 3-O-sulfo position) and non radiolabeled heparin to mPF4.  
During this analysis, we varied the amount of cold heparin in each reaction and calculated the 
amount bound that was captured using nitrocellulose paper.  This KD was determined to be 
about 14 nM. 
Affinity Co-electrophoresis 
 Affinity co-electrophoresis (ACE) is another common method for determining the 
binding affinity of polysaccharides to proteins (118).  In this approach, the amount of protein, 
not the amount of polysaccharide, is varied.  We utilized an ACE gel to determine the 
binding affinity of our mPF4 to heparin.  The binding affinity of medicinal heparin that was 
35
S-labeled at the 3-O position was 68 nM.  KD was determined by plotting the normalized 
migration distance of the polysaccharide through the well divided by the concentration of 
PF4 within the lane versus the concentration of mPF4 within the lane (Figure 28). 
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Figure 28:  Affinity Co-electrophoresis is a general method for determining the binding 
affinity of polysaccharides.  Displayed in this figure is an ACE gel run of [
35
S] heparin 
radiolabeled at the 3-O position and mPF4 with concentrations varying from 0-4µM. 
 
Section 2: Decreasing Binding Affinity of Anticoagulant Heparan sulfates for mPF4 
 Platelet factor 4 (PF4) is a highly positively charged protein (Figure 29).  Interaction 
between PF4 and the highly negative heparin is thought to be due to charge-charge 
interactions.  The interaction between the two lead to the formation of large macromolecular 
structures (25).  In this portion on the chapter, I will describe methods for decreasing the 
overall negative charge to heparan sulfate structures to decrease their potential for binding 
PF4. 
 88 
 
 
Figure 29:  Electrostatic map of murine Platelet Factor 4.  The blue color represents the 
highly positive regions around the tetramer.  The red color represents highly negatively 
charged regions around the tetramer.  This model was generated using PyMol and the PF4 
crystal structure (PDB ID: IF9Q). 
 
 Using the heparan sulfate families synthesized in Chapter III, we are able to generate 
a schematic for the synthesis of species within these families that have varied sulfation 
amounts (Figure 30).  I began these studies by identifying structurally simple heparan sulfate 
families that exhibited anticoagulant activity.  The two most structurally simple familes were 
2 and 7 as they contained the fewest types of sulfations and overall modifications of all of the 
AT-binding familes.  In this section, we utilized families 2 and 7 as a „template‟ for creating 
species of heparan sulfates that have a decreased propensity for PF4.  These new species will 
be synthesized and will vary in either the amount of 6-O-sulfation or N-sulfation they 
contain.  
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Figure 30: Flow chart of the strategy for developing heparan sulfate structures with 
anticoagulant activity with decreased affinity for PF4.  Beginning with heparin as a 
template, families of unique heparan sulfate families were biosynthetically synthesized.  Two 
families, family 7 (structure at the left) and 2 (structure at the right) were the chosen 
candidates for reduction of PF4 affinity since they contain the same types of sulfation but 
vary in flexibility due to the presence of the IdoUA unit in family 7.  These two families 
were then modulated at both 6-O and N- positions to create 4 species of each type of 
modulation.   
 
The effects of varying 6-O-sulfation of AT binding polysaccharides 
 In the first group of species (Group 1A and Group 1B), we varied the amount of 6-O-
sulfation per microgram of polysaccharide.  The schematic of synthesis of these species are 
provided below (Figure 31).  Synthesis of these species began with N-sulfating heparosan.  
At this point, four reactions were started containing varying microgram amounts of N-sulfo 
heparosan (the reactions contained between 0.5-4 µg of N-sulfo heparosan).  In group 1A, 
epimerase was added to the reaction; in group 1B, this addition was omitted.  The same 
amount of PAPS (both radiolabeled and non-radiolabeled) and 6-OST isoforms 1 and 3 were 
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added to each reaction.  After purification of the 6-O-sulfated species, 3-O-sulfation was then 
added to generate the AT binding species. 
 
Figure 31:  Schematic for generating Group A heparan sulfate species with varied 
amounts of 6-O-sulfation.  In each reaction, the amount of N-sulfo heparosan ranged from 
0.5-4 µg to vary the ratio between the sulfo donor, PAPS, and the polysaccharide.  Group 1A 
included the IdoUA unit introduced by epimerase, while Group 1B did not. 
 
Structural information 
 Structural information for these species was conducted in two ways, via disaccharide 
analysis and the number of picomoles (pmols) of sulfo groups transferred per microgram 
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polysaccharide.  Each species of polysaccharide were derived from the same N-sulfo 
heparosan.  This heparosan was sulfated to about 97% completion using N-sulfotransferase 
following deacetylation.  Following N-sulfation, the substrate species were 6-O-sulfated 
using 6-OST isoforms 1 and 3.  The number of picomoles of sulfo groups per microgram of 
polysaccharide are displayed in the figure below (Figure 32).  The number of picomoles was 
determined using the specific activity of the enzyme combination.  In the species containing 
iduronic residues (Group 1A, red bars), there is a steady trend of decreasing sulfo groups per 
microgram as the microgram of polysaccharides increased.  However, in the group without 
iduronic residues (Group 1B, blue bars), the trend is slightly more difficult to see.  However, 
there is also a trend downward in sulfation, just not as significant when compared to group 
1A.  We account these differences in trend to the substrate specificity of the enzymes. 
 
Figure 32:  The number of picomoles transferred per microgram of heparan sulfate 
polysaccharide.  This number was calculated using the specific activity of the combination 
of 6-OST isoforms 1 and 3.  The amount of pmols of sulfo groups transferred for Group 1A 
are shown with the red bars while the amount of pmols of sulfo groups transferred for Group 
1B are displayed in the blue bars. 
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PF4 binding percentage 
 The first test of these species was to see if decreasing the overall 6-O-sulfation of 
these HS did in fact decrease their propensity for PF4.  Using a qualitative experiment, we 
determined the percentage of our substrate species that bound PF4 at different concentrations 
of PF4.  We performed this assay for both groups 1A and 1B (Figure 31).  The top panel of 
Figure 33 shows the percentage of polysaccharides bound to PF4 for group 1A (derived from 
family 7, with the iduronic residue).  In this panel, there is variance between species, but no 
common trend.  As for group 1B, in the bottom panel, there is similar variance among the 
binding percentages, but no definite trend.  Also, when comparing Group 1A and 1B, the 
flexibility incorporated in the polysaccharides of Group 1A does not have a drastic effect on 
their binding to PF4 when compared to 1B.  All together, this data showed that variance of 6-
O-sulfation does have a minimal effect on platelet factor 4 binding and increased flexibility 
of these polysaccharides does not have an effect.   Due to the lack of significant decrease in 
binding to platelet factor 4, we abandoned these species for further studies. 
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Figure 33:  Percent binding of Group 1A (top panel) and Group 1B (lower panel) with 
varied 6-O-sulfation to PF4 as determined by dot blot analysis.  From 0.5ug to 4ug 
samples, the amount of sulfo groups transferred decreased per microgram of polysaccharide 
in general. 
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The effects of varying N-sulfation of AT binding polysaccharides 
 In the second group of species (Group 2A and Group 2B), we varied the amount of N-
sulfation per microgram of polysaccharide.  Again, Group A mirrors family 7 (as it contains 
IdoUA units) and group B mirrors family 2.  The schematic of synthesis of these species is 
provided below (Figure 34).  Synthesis of these species began with creating four reactions 
containing partially N-sulfating heparosan.  This was controlled by adjusting the amount of 
PAPS provided in the reaction.  The ratio of PAPS added to the reaction was determined by 
the number of free amine groups present per microgram of deacetylated polysaccharide.  The 
amount of PAPS added ranged from 0.25x to 2x the amount of free amine groups.   
Immediately following N-sulfation, the unsubstituted N-groups were re-acetylated.  This step 
was necessary in order for recognition by the subsequent enzymatic modifications.  Similar 
to the previous groups, in group 2A, epimerase was added to the reaction and in group 2B, 
this addition was omitted.  The same amount of PAPS (both radiolabeled and non-
radiolabeled) and 6-OST isoforms 1 and 3 were added to each reaction.  After purification of 
the 6-O-sulfated species, 3-O-sulfation was then added to generate the AT binding species. 
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Figure 34: Schematic for generating heparan sulfate species (Group 2A and 2B) with 
varying N-sulfation content.  In each of these reactions, by limiting the amount of the sulfo 
donor, PAPS, I was able to generate N-sulfo heparosan with varied amounts of N-sulfation. 
 
Structural information 
 Structural information for these species was conducted in two ways, via disaccharide 
analysis and the number of picomoles (pmols) of sulfo groups transferred per microgram 
polysaccharide.  Each species of polysaccharide were derived from the same stock of 
heparosan.  This heparosan was completely deacetylated using 2 M sodium hydroxide and 
then N-sulfated; however, this N-sulfation was varied between species groups.  The variance 
of N-sulfation was checked by calculating the number of picomoles of sulfo groups 
transferred and confirmed by the disaccharide analysis profile that was analyzed on the 
HPLC (Appendix Figure A4).  Following N-sulfation, the substrate species were 6-O-
sulfated using 6-OST isoforms 1 and 3.  The number of picomoles of sulfo groups transferred 
to the 6-O position per reaction are displayed in the figure below (Figure 35).  The number of 
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picomoles was determined using the specific activity of the enzyme combination.  In the 
species containing iduronic residues (Group 2A, red bars), there is a steady trend upward of 
sulfo groups per reaction as the amount of N-sulfation increased, with the exception of the 
last species.  These were similar in the number of sulfo groups as we may have met 
saturation.  In the group without iduronic residues (Group 2B, blue bars), there is also a trend 
upward in sulfation.  Again, the difference in sulfation between Group 2A and Group 2B can 
be attributed to their substrate specificities. 
 
Figure 35:  The number of picomoles of sulfo groups transferred to heparan sulfate 
polysaccharides calculated using the specific activity of 6-O-sulfotransferase.   Group 2A 
is represented with the rd bars while Group 2B is represented by the red bars.  In general, as 
the amount of N-sulfation increased, the amount of 6-O-sulfation increased.  However, in 
Group 2A, there appears to be saturation of the amount of 6-O-sulfo groups that are added in 
the polysaccharide species containing the highest amounts of N-sulfation. 
 
PF4 binding percentage 
 The first test of these species was to see if decreasing the overall N-sulfation of these 
heparan sulfates did in fact decrease their propensity for PF4.  Using the dot blot, a 
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qualitative experiment, we determined the percentage of our substrate species that bound PF4 
at different concentrations of PF4.  We performed this assay for both groups 2A and 2B 
(Figure 35).  The top panel of Figure 36 shows the percentage of polysaccharides bound to 
PF4 for group 2A (derived from family 7, with the iduronic residue).  In this panel, there is 
variance between species and a trend showing that less N-sulfation led to less binding to PF4 
as shown at the highest concentration of PF4.  As for group 2B, in the bottom panel, there is 
similar variance among the binding percentages; but clearly, the heparan sulfate with the 
highest amount of N-sulfation exhibits the highest binding to PF4, again shown most 
dramatically at the highest concentration of PF4.  When comparing the top to the bottom 
panel at the same concentration of PF4, the incorporation of the flexible iduronic units in the 
top panel (Group 2A) did not decrease the amount of polysaccharides bound to PF4 when 
compared to Group 2B at lower amount of N-sulfation as drastically as modulation of the 6-
O-sulfation.  Taken together, this data showed that variance of N-sulfation at the beginning of 
synthesis has a profound effect on PF4 binding. 
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Figure 36:  Percentage binding of heparan sulfate species with varying N-sulfation to 
PF4 as determined by the dot blot.  Group 2A (with IdoUA units) is shown in the top panel 
while Group 2B is shown in the bottom panel.  0.25x to 2x represent the amount of PAPS 
added to the reaction, where from 0.25x to 2x, the amount of N-sulfation increased. 
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AT binding percentage versus PF4 binding percentage 
 Since the species derived from family 2 exhibited the most variance in binding 
percentage to PF4, we conducted qualitative binding studies for their binding to antithrombin 
(AT).  In this assay, substrates were separated using a prepared AT column.  The best binders 
were eluted from the column with high salt.  Each of the biosynthetic species bound to AT 
around 30-48%.  This was compared to heparin‟s binding of about 59% (Figure 37). 
 
Figure 37: The qualitative binding percentage of the biosynthetic heparan sulfates and 
heparin to AT.  These binding percentages were determined using AT fractionation. 
 
 Now that we have qualitative binding data for binding to both PF4 and AT, we began 
to assess whether or not we could segregate these biological activities.  Plotting the 
percentage of the species bound to AT versus the amount bound to PF4 suggests that the 
propensity for these heparan sulfate species to perform in these functions could begin to be 
separated (Figure 38).  Each of the polysaccharides bound to AT around the same amount, 
however, as the amount of N-sulfation increased, there was an increase in binding to PF4.  
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We chose three of these points for further study, the 0.25x, 0.5x and 2x species as they 
represented the high, medium and low binders to PF4. 
 
Figure 38:  Graph of the percentage of Group 2B samples that bound AT versus the 
percentage of samples that bound PF4.  The red point represents the binding of medicinal 
heparin.  From left to right, the black points represent the heparan sulfate species with 
increasing amounts of N-sulfation. 
 
AT affinity (KD) 
 The binding affinities to AT were determined for the 0.25x, 0.5x and 2x samples 
using affinity co-electrophoresis (Table 7).  Each of the heparan sulfates exhibited a KD 
within the nanomolar range and compared well to heparin.  It is noted that the KD of the 2x 
sample had a KD four times that of the 0.5x sample.  However, indication that this binding 
affinity would be vastly different from the others was not displayed during the previous 
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qualitative testing.  These KDs indicated that these substrates would maintain their 
anticoagulant activity. 
Table 9:  KD’s for Group 2B species binding to antithrombin. 
Samples KD (nM) 
0.25x N-Sulfation 70 
0.5x N-Sulfation 40 
2x N-Sulfation 200 
Heparin 10 
The KDs were determined using ACE with antithrombin concentrations ranging from 0-1000 
nM.   
 
PF4 affinity (KD) 
 The binding affinities to PF4 were determined for the 0.25x, 0.5x and 2x samples 
using affinity co-electrophoresis (Table 8).  Only the 2x sample displayed a KD within the 
range of this test.  The 0.25x and 0.5x samples showed no binding within the scope of this 
assay, therefore, it can be deemed that the KD of these polysaccharides to PF4 is greater than 
4 µM.  These data reconfirms the decreased binding of substrates 0.25x and 0.5x.  However, 
each of these samples had the potential to exhibit anticoagulant activity.  This data taken 
together showed that this biosynthetic approach can be used to separate the biological 
functions of heparin structures. 
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Table 10: KD's for Group 2B species binding to platelet factor 4. 
Samples  KD (nM)  
0.25x  N-sulfation  Out of range*  
0.5x  N-Sulfation  Out of range*  
2x N-Sulfation  150 
Heparin  70 
These KD‟s were determined using ACE.  The range of mPF4 used was between 0 and 4 µM.  
(*) Denotes that the KD could not be determined based on the limits of this assay.  The limits 
of this assay suggests that the KD of these two samples is greater than 4 µM. 
 
Anticoagulant activity determined via Anti-Xa and Anti-IIa assays 
 Since each of the species exhibited a reasonable binding affinity to AT, we tested 
each of these samples for both their Anti-Xa and Anti-IIa activities.  We compared these 
samples with medicinal heparin and heparan sulfate (our negative control).  Each of our 
substrates maintained a reasonable amount of anticoagulant activity when compared to 
heparin (Figure 39).    
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Figure 39:  Anti-Xa and Anti-IIa activities of Group 2 biosynthetic heparan sulfates 
compared to medicinal heparin and heparan sulfate (negative control). 
 
Conclusions  
  In conclusion, I was able to express murine platelet factor 4 in high and stable 
quantities for in vitro assays.  I was also able to use this mPF4 to probe binding affinities of 
biosynthetic heparan sulfate structures.  Using a biosynthetic approach, I probed the structure 
and activity relationship between heparan sulfate species and obtained heparan sulfates that 
maintained anticoagulant activity, but exhibited a decreased propensity for binding to platelet 
factor 4.  During the chemoenzymatic synthesis, modulation of N-sulfation was the most 
effective in decreasing the heparan sulfate species binding to platelet factor 4, as compared to 
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modulation of flexibility and 6-O-sulfation content.  It has been noted that the degree of N-
sulfation affects the efficiency of subsequent sulfations due to the substrate specificity of 
these sulfotransferases.  By modulating N-sulfation, we were then able to modulate the 
amount of 6-O and 3-O sulfations as well.  Starting sulfation modulation at the 6-O position 
yielded a small decrease in binding to PF4, but it does not yield as great of an effect as 
modulation at the N-position.  However, each of the species with modulation at the N-
position was able to maintain its anticoagulant activity, in spite of its decreased affinity for 
platelet factor 4.  In conclusion, modulation of the initial sulfation can dictate the heparan 
sulfate species ability to bind a specific protein, but does not necessarily affect its biological 
activity.  The chemoenzymatic approach is effective for studying the SAR of heparan sulfate 
polysaccharides and also provides a means to begin selection of biological activity.   
  
  
CHAPTER V: 
 
CONCLUSIONS 
 
 Heparan sulfate (HS) is a major component on the mammalian cell surface and in the 
extracellular matrix and has a wide range of biological functions. There is considerable 
interest in developing HS-based drugs to inhibit tumor growth, bacterial viral infections, and 
bacterial infections and to modulate inflammatory responses. It is clear that an enzymatic 
approach is a viable method for generating the polysaccharides with different sulfation 
patterns and biological functions. The synthesis can be conducted in parallel to produce a 
large number of compounds by adjusting the levels of individual enzymes. The work 
presented in this study has shown that utilizing a biosynthetic approach to synthesize of 
polysaccharides is a viable approach to not only study the structure and activity relationships 
of heparan sulfate polysaccharides, but also to begin to segregate the functions of these 
polysaccharides.  Within this work, I presented novel heparan sulfate classes that exhibit 
anticoagulant activity but have decreased activity in both proliferation and binding to platelet 
factor 4.  A summary of the SAR can be seen below in Figure 40: 
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Figure 40:  Summary of the SAR of these synthetic polysaccharides.  The blue arrows 
represent the positions most critical for anticoagulant activity, the red arrow represents the 
motif most critical for PF4 binding and the purple arrows show the most critical motifs for 
proliferative activity. 
 
 I showed that N-, 6-O, and 3-O-sulfations are the most critical for exhibiting 
anticoagulant activity, modulation of the degree of N-sulfation at the beginning of synthesis 
has the most effect on binding to platelet factor 4 and the lack of the Ido2S residue within a 
polysaccharide decreases its propensity for proliferative activity.  In the coming years of the 
glycomics era, continuing efforts to improve the enzymatic synthesis of HS will lead to the 
development of novel therapeutic reagents. 
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Appendix A 1:  Amino acid analysis data provided by the Molecular Structure Facility 
at UC Davis for Trx-mPF4 after cleavage of the tag. 
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